Distinct Transcriptomes Define Rostral and Caudal Serotonin Neurons

Christi J. Wylie,¹ Timothy J. Hendricks,³ Bing Zhang,⁴ Lily Wang,⁵ Pengcheng Lu,⁴ Patrick Leahy,² Stephanie Fox,¹ Hiroshi Maeno,¹ and Evan S. Deneris¹

¹Department of Neurosciences and ²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio 44106, ³Molecular Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, and Departments of ⁴Biomedical Informatics and ⁵Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

The molecular architecture of developing serotonin (5HT) neurons is poorly understood, yet its determination is likely to be essential for elucidating functional heterogeneity of these cells and the contribution of serotonergic dysfunction to disease pathogenesis. Here, we describe the purification of postmitotic embryonic 5HT neurons by flow cytometry for whole-genome microarray expression profiling of this unitary monoaminergic neuron type. Our studies identified significantly enriched expression of hundreds of unique genes in 5HT neurons, thus providing an abundance of new serotonergic markers. Furthermore, we identified several hundred transcripts encoding homeodomain, axon guidance, cell adhesion, intracellular signaling, ion transport, and imprinted genes associated with various neuro-developmental disorders that were differentially enriched in developing rostral and caudal 5HT neurons. These findings suggested a homeodomain code that distinguishes rostral and caudal 5HT neurons. Indeed, verification studies demonstrated that Hmx homeodomain and Hox gene expression defined an Hmx⁺ rostral subtype and Hox⁺ caudal subtype. Expression of engrailed genes in a subset of 5HT neurons in the rostral domain further distinguished two subtypes defined as Hmx⁺En⁺ and Hmx⁺En⁻. The differential enrichment of gene sets for different canonical pathways and gene ontology categories provided additional evidence for heterogeneity between rostral and caudal 5HT neurons. These findings demonstrate a deep transcriptome and biological pathway duality for neurons that give rise to the ascending and descending serotonergic subsystems. Our databases provide a rich, clinically relevant resource for definition of 5HT neuron subtypes and elucidation of the genetic networks required for serotonergic function.

Introduction

Genetic perturbation of embryonic brain serotonin (5HT) neuron gene expression causes developmental alterations in numerous rodent behaviors (Hendricks et al., 2003; Hodges et al., 2008; Lerch-Haner et al., 2008) and is thought to significantly contribute to susceptibility of human emotional and stress-related neurodevelopmental pathogenesis in adulthood (Ansorge et al., 2007). Evidence in support of these ideas is primarily derived from the study of genes encoding the rate-limiting biosynthetic enzyme tryptophan hydroxylase 2 (TPH2), the 5HT transporter (Sert), and the serotonin 1a autoreceptor (Leonardo and Hen, 2006; Holmes, 2008; Le François et al., 2008). As these proteins operate in complex networks of poorly defined cellular regulatory pathways (Prasad et al., 2005), many other genes are likely to be important for serotonergic function, and many of them may be relevant to human mental disease pathogenesis. Yet their iden-

This work was supported by National Institute of Mental Health Silvio Conte Center Grant P50 MH078028 (Project 1) to E.S.D. We thank Randy Blakely, Elaine Sanders-Bush, Doug McMahon, Ron Emeson, Pat Levitt, other members of Vanderbilt Conte Center, and Robert Miller in the Case Western Reserve University Neuroscience Department for helpful suggestions and comments on this project. We thank Kathy Lobur for help with timed pregnancies and genotyping. We thank A. Joyner and Brian Bai for pan-engrailed antiserum and T. Jessell for Hox antibodies.

Correspondence should be addressed to Evan S. Deneris, Department of Neuroscience, School of Medicine, Case Western Reserve University, 2109 Adelbert Road, Cleveland, OH 44106-4975. E-mail: esd@case.edu. D0I:10.1523/JNEUROSCI.4656-09.2010

Copyright © 2010 the authors 0270-6474/10/300670-15\$15.00/0

tity is largely obscure in part because of a lack of an approach to isolate 5HT neurons for comprehensive gene expression profiling of this CNS cell type.

Gene expression profiles of 5HT neurons may be complex despite their common monoaminergic character if, as is evident, these cells are heterogeneous. 5HT neurons can be distinguished according to their axonal trajectories and physiological properties (Beck et al., 2004; Kocsis et al., 2006). Rostral 5HT neurons, born anterior to rhombomere 4 (r4) give rise to ascending axonal projections, which modulate circuitry needed for emotional responses, circadian rhythms, and energy balance (Lucki, 1998; Sodhi and Sanders-Bush, 2004). A caudal cluster, posterior to r4 gives rise to descending pathways, which modulate a diversity of physiological processes including cardiorespiratory homeostasis, thermoregulation, and nociception (Mason, 2001; Erickson et al., 2007; Zhao et al., 2007; Gargaglioni et al., 2008; Hodges et al., 2008). Differences in progenitor identities (Jacob et al., 2007; Lillesaar et al., 2007), extrinsic signaling dependencies (Ye et al., 1998), transcription factor requirements (Hendricks et al., 2003), and distinct rhombomere-specific neuron sublineages (Jensen et al., 2008) suggest complexity in rostrocaudal serotonergic differentiation programs that generate these cells. These potentially distinct programs may direct different patterns of 5HT neuron gene expression and account for the diversity of behaviors and physiological processes under serotonergic modulation as well as the large number of neuropsychiatric disorders in which seroto-

Received Sept. 17, 2009; revised Oct. 21, 2009; accepted Nov. 14, 2009.



Figure 1. ePet-EYFP expression marks rostral and caudal 5HT neurons in the embryonic ventral hindbrain. *A*, Whole-mount view of an ePet-EYFP transgenic brain at E14.5. Both rostral and caudal 5HT neuronal cell bodies and axonal projections were brightly marked by EYFP fluorescence. *A'*, High-magnification view ($8 \times$) of caudal 5HT axonal projections to the spinal cord. *B*–*D*, Tiled confocal *z*-stack images of 5HT immunoreactivity (red) and EYFP fluorescence at E12.5 (*B*, sagittal view) and at E14.5 in the caudal (*C*, sagittal view) and rostral (*D*, coronal view) domains. Scale bars: *B*, 100 µm; *C*, *D*, 200 µm.

nergic dysfunction has been implicated (Holmes, 2008). Few genetic markers distinguish differentiated 5HT neurons, however, and therefore their molecular differences are poorly defined.

Whole-genome profiling is a powerful approach for analysis of molecular complexity in CNS neuronal and glia cell types and the developmental programs specifying their diversity (Sugino et al., 2006; Cahoy et al., 2008). Here, we report a purification protocol for enrichment of embryonic postmitotic 5HT neurons followed by microarray analysis of 5HT neuron gene expression profiles. Our microarray, verification, and bioinformatics studies identify several hundred genes and many biological pathways whose expression distinguishes rostral and caudal 5HT neurons. Our transcriptome datasets provide an abundance of new markers to enable molecular classification of 5HT neuron subtypes and a rich resource for identification of new serotonergic genes of potential relevance to mental disease pathogenesis.

Materials and Methods

Transgenic mice. ePet-EYFP mice were generated in a C57/SJL background. Embryos were genotyped either by PCR with primers 5'-GAA CTC CAG CAG GAC CAT GT-3' and 5'-TAT ATC ATG GCC GAC AAG CA-3' or by a fluorescence dissecting microscope.

Dissection of ePet-EYFP⁺ neural tubes. Pregnant mice [embryonic day 0.5 (E0.5) defined as the morning of plug formation] were killed by cervical dislocation in accordance with Institutional Animal Care and Use Committee regulations. E12.5 embryos were removed from uteri into ice-cold L15 media (Invitrogen). Hindbrains were dissected and visualized under an inverted fluorescent dissecting microscope to identify ePet-EYFP⁺ transgenics. A nontransgenic embryo was identified and processed simultaneously as a negative control to gate for background fluorescence on the cell sorter. Hindbrains were dissected into rostral and caudal

regions using the absence of YFP fluorescence in rhombomere 4 as a landmark. Specifically, the neural tube was isolated from the mesencephalic flexure to the spinal cord and cut at the pontine flexure to separate rostral and caudal hindbrain regions (see Fig. 2A).

Cell dissociation. Rostral and caudal hindbrains were enzymatically digested in $1\times$ trypsin-EDTA (Invitrogen) diluted in Ca^{2+/} Mg²⁺-free DPBS (Invitrogen) at 37°C for 17 min. Tissues were washed three times in icecold Leibovitz L15 media (Invitrogen). Samples were resuspended in L15 containing 0.1% BSA (Invitrogen) and 0.1 μ g/ml DNase (Sigma) and then mechanically dissociated by gentle trituration with a fire-polished glass pipette to create a single-cell suspension. Cells were pelleted and resuspended in L15 containing 0.1% BSA.

Flow cytometry. Cells were passed through a 40 µm filter and immediately sorted on a Becton Dickinson FACS Aria digital cell sorter equipped with an argon laser providing excitation of 200 mW at 488 nm. YFP fluorescence was detected with the standard FL2 filter set (560 nm dichroic, 585/42 nm bandpass). Sort pressure was 35 psi with an 85 μ m nozzle tip driven at 39.5 kHz. Maximum event rate was conservatively limited to 5000/s. Forward scatter height versus width gating was used to eliminate aggregates. YFP fluorescent cells were identified by characteristic red versus orange fluorescence and were sorted directly into tubes containing Trizol (Invitrogen) for subsequent RNA extraction or into L15 media for confirmation of sort purity. A typical sort with 4-5 transgenic embryos at E12.5 yielded

~45,000 rostral YFP⁺ and 30,000 caudal YFP⁺ 5HT neurons. Using this protocol, we collected ~200,000 cells for each of the four cell groups to be profiled: R^+ (rostral YFP⁺), R^- (rostral YFP⁻), C^+ (caudal YFP⁺), and C^- (caudal YFP⁻).

RNA isolation, amplification, and microarray hybridization. Total RNA was isolated after the addition of tRNA as carrier and RNA quality was inspected with a Bioanalyser 2100 (Agilent). One-round amplification was performed using the MessageAmp II Kit (Ambion). In vitro transcription with biotin incorporation (Bioarray High Yield RNA Transcript Labeling, Enzo) was used to generate cRNA probes. The quantity of cRNA was measured by Nanodrop 1000 (Nanodrop Technologies). Ten micrograms of cRNA for each cell type were fragmented and hybridized overnight at 42°C to Affymetrix whole-genome arrays (Mouse Genome 430 2.0). Each Affymetrix 430 2.0 array contains 45,037 oligonucleotide probe sets, which represent 20,832 unique genes. After hybridization, the chips underwent stringency washes in a Genechip Fluidics Station (Affymetrix) and were scanned at high resolution (Affymetrix High Density GeneChip Scanner 3000). Three biological replicates from different litters, independent FACS isolation, amplification, and hybridization were performed to assess reproducibility. DAT files were later used to generate CEL files. Affymetrix GCOS using MAS 5.0 statistical algorithms was used to convert CEL files into Excel spread sheets. Standard quality assessment procedures were performed for all hybridizations according to Affymetrix recommendations.

Microarray data processing. Present/Absent calls for each probe set were calculated with Affymetrix MAS 5.0 package of Bioconductor (Reimers and Carey, 2006). Default parameters were used for the calculation. CEL files from 12 chips were normalized using the Robust MultiChip Averaging (RMA) algorithm as implemented in Bioconductor (Reimers and Carey, 2006).

Multiple-group comparison and hierarchical clustering. The ANOVA test in the Limma package (Smyth, 2005) was used to identify probe sets

that were differentially expressed across the four test groups. The *p* values generated from the ANOVA test were further adjusted using the Benjamini and Hochberg correction (Benjamini and Hochberg, 1995). In this comparison, differentially expressed probe sets were selected based on two criteria: (1) adjusted *p* values <0.001, and (2) at least a twofold change between the groups with highest and lowest average expression values. Hierarchical clustering analysis (Eisen et al., 1998) was then applied to the selected probe sets. Average linkage was used in the clustering analysis with Pearson's correlation coefficient as the similarity measurement.

Pairwise comparisons. For pairwise comparisons, the t test in the Limma package was used to identify differentially expressed probe sets between the two groups under comparison. The implementation of t test in Limma uses an empirical Bayes method to moderate the SEs of the estimated log-fold changes. This results in more stable inference and improved power, especially for experiments with small number of arrays. The *p* values generated from the *t* test were further adjusted using the Benjamini and Hochberg correction (Benjamini and Hochberg, 1995) to account for multiple comparisons. An adjusted p value of 0.01 (i.e., 1% false discovery rate) was used to select differentially expressed probe sets.

Knowledge-guided gene set-level analysis. We used the mixed models approach (Wang et al., 2008) to assess coordinated changes of genes at the gene set level in serotonin neurons. Gene sets derived from the Gene Ontology (GO) were downloaded from the Molecular Signatures Database (MSigDB) (http://www.broad. mit.edu/gsea/msigdb/index. jsp). For each gene set, this approach compares the average gene expression levels of the two groups (e.g., serotonin neurons vs nonserotonin neurons) for gene sets versus other genes while controlling for correlations between genes. Mixed models analysis uses continuous evidence from each gene so that the results do not depend on any significance cutoff for single genes as in con-



Figure 2. Purification and expression profiling of rostral and caudal 5HT neurons. *A*, E12.5 ePet-EYFP neural tubes were dissected and incisions made at the mesencephalic flexure, pontine flexure, and spinal cord to separate the rostral and caudal domains. *B*, Single-cell suspensions of rostral and caudal neural tubes were subjected to FACS. EYFP ⁺ cells were collected in gate P7 (top) and nonfluorescent cells were collected in gate P8 (bottom). The fluorescent and nonfluorescent fractions were separated by one log unit to ensure pure populations for gene expression profiling. *C*, Sorting efficiency was verified by examining purified cells under fluorescence (top) and phase-contrast (bottom) microscopy. *D*, RNA was isolated from rostral YFP⁺ (R⁺), rostral YFP⁻ (R⁻), caudal YFP⁺ (C⁺), and caudal YFP⁻ (C⁻) sorted cells and then assayed by Taqman RT-PCR for two known 5HT neuron-specific genes, Fev and Tph2. *E*, Total RNA from 200,000 sorted cells each for rostral 5HT YFP⁺ (R⁺), rostral non-5HT (R⁻), caudal 5HT YFP⁺ (C⁺), and caudal non-5HT (C⁻) was used for one round of amplification to generate cRNA probes. *F*, *G*, Enriched expression of well established highly expressed (*F*) and more moderately expressed (*G*) markers of 5HT neurons were detected in R⁺ and C⁺ neurons by microarray hybridization. The *y*-axis equals the gene expression level determined by MAS 5.0. Error bars represent SEM. Scale bars: *A*, *C*, 100 μ m.

ventional overrepresentation analysis. It was shown to have more favorable statistical properties compared to traditional gene set analysis methods (Wang et al., 2008). Because many gene sets were examined, to control for the rate of false-positive findings by chance, we adjusted nominal *p* values using Bonferroni correction.

Double-label in situ hybridization/immunohistochemistry. DIG-labeled antisense probes were synthesized with digoxigenin-11-UTP according to the manufacturer's instructions (Roche). Tissues were fixed with 4% paraformaldehyde overnight and then cryoprotected in 30% sucrose. Ten to twenty micrometer cryostat sections were collected on Superfrost Plus slides (Fisher). Sections were fixed again for 5 min, washed three times with $1 \times$ PBS, treated with proteinase K (1 µg/ml) for 3 min, washed three times with 1× PBS, acetylated in 0.35% (v/v) acetic anhydride at room temperature in 100 mM triethanolamine pH 8.0 for 10 min, and then rinsed three times in $1 \times$ PBS. Sections were prehybridized for 1 h at room temperature in hybridization buffer (50% deionized formamide, 5× SSC, 5× Denhardt's solution, 250 μ g/ml Baker's yeast tRNA, 500 µg/ml salmon sperm DNA). Probe was diluted 1:100 in hybridization buffer and applied to slides, which were then sealed with Hybrislip coverslips (Grace Biolabs). Hybridization was performed overnight at 65-68°C. The next day coverslips were removed in 5× SSC. Sections were then washed for 2 h in $0.2 \times$ SSC at 65–68°C. Sections were

then equilibrated in $1\times$ B1 (100 mm Tris, pH 7.4, 150 mm NaCl) for 10 min, blocked for 1 h in 10% heat-inactivated goat serum diluted in B1, and then incubated overnight at 4°C with sheep anti-DIG-alkaline phosphatase-conjugated Fab fragments (Roche) diluted 1:5000 in blocking buffer. The next day slides were washed 3×15 min in $1 \times B1$, equilibrated in freshly prepared B2 (300 mM Tris, pH 9.5, 300 mM NaCl, 150 mM MgCl₂) for 10 min, and then developed in chromogen solution containing 340 µg/ml NBT, 180 µg/ml BCIP, and 240 µg/ml levamisole (all Sigma) in B2 at room temperature for 2–16 h. For double labeling, slides were washed 3×5 min in $1 \times$ PBS, blocked 1 h in 10% goat serum in $1 \times PBST$, and incubated with anti-rabbit GFP (Clontech) at 1:1000 overnight at 4°C. Sections were then washed 3×5 min in $1 \times$ PBS and incubated with a 1:1000 dilution of biotinylated goat anti-rabbit IgG antibody for 2 h at room temperature. Horseradish peroxidase staining was performed using the avidin-biotin-peroxidase complex (Vectastain ABC kit, Vector Laboratories) and SigmaFast DAB tablets (Sigma). Sections were dehydrated through graded ethanols and xylene and coverslipped with DPX (Electron Microscopy Sciences).

Immunohistochemistry and antibodies. Immunohistochemistry was performed on 20 μ m cryostat sections from embryos that were fixed in 4% PFA for 1–2 h and then cryoprotected in 30% sucrose. Pan-engrailed antiserum was a gift from Alexandra Joyner (Sloan-Kettering Institute). Hox antibodies were a gift from Thomas Jessell (Columbia University

Medical Center). Pan-Meis antibody was a gift from Steve O'Gorman (Case Western Reserve University). Dilutions were 1:8000 for rabbit anti-HoxA3, 1:5000 for rabbit anti-HoxC4, 1:1000 for rabbit anti-pan-Meis, and 1:100 for rabbit anti-pan-engrailed antibodies. Goat anti-rabbit Texas Red secondary antibody (Jackson ImmunoResearch Laboratories) was used at 1:400.

Confocal microscopy. Twenty to thirty micrometer sections were imaged on a Zeiss LSM 510 Meta confocal microscope. For z-stacks, images were collected every 2–3 μ m and compressed using Zeiss LSM Image software.

Taqman quantitative real-time reverse transcription-PCR. Total RNA was extracted from FACS-isolated cells according to the Trizol method (Invitrogen). R⁺, R⁻, C⁺, and C⁻ RNA samples were delivered to the Gene Expression and Genotyping Facility at Case Western Reserve. Samples were then converted to cDNA and then assayed by Taqman (Applied Biosystems) in triplicate for candidate gene confirmation. The C_T (cycle number at threshold) was used to calculate the relative amounts of mRNA molecules for a given gene. The C_T of each target gene was normalized by subtracting the C_T value of the housekeeping gene β -actin, which gave the value ΔC_T . The difference in the ΔC_T from the cell type of interest and a control cell type gave $\Delta\Delta C_{T}$. The relative quantitative change was shown as $2^{-\Delta\Delta C_{T}}$. Taqman assay IDs for each gene are as follows: Fev, Mm00462220_ n1; Tph2, Mm00557717_m1; Rnf112 (Zfp179), Mm008396908_g1; Zcchc12, Mm00511603_m1; Tox, Mm00455231_m1; 2010204K13RIK, Mm01971390_s1; AW551984, Mm00724626_m1; 1700042O10RIK, Mm01191108_m1; Hmx2, Mm01165724_m1; Hmx3, Mm00433957_g1; Pou3f1, Mm00843534_s1; En1, Mm00438709_m1; En2, Mm00438710_m1; HoxA3, Mm01326402_m1; HoxB3, Mm00650701_m1; HoxD3, Mm00439371_m1; HoxA4, Mm01335255_g1; HoxB4, Mm00957964_ m1; HoxC4, Mm00442838_m1; HoxA5, Mm00439362_m1; HoxB5, Mm00657672_m1; HoxC5, Mm00433971_m1.

Results

Purification and gene expression profiling of embryonic rostral and caudal 5HT neurons

The ePet-EYFP transgenic mouse line expresses enhanced yellow fluorescent protein (EYFP) specifically in adult 5HT neurons (Scott et al., 2005). To determine whether this line would be suitable for identification and purification of embryonic 5HT neurons we determined the pattern of EYFP expression in the developing hindbrain. Both rostral and caudal embryonic 5HT neurons and their axons could be readily visualized by expression of YFP in the ePet-EYFP line (Fig. 1 and data not shown). YFP was colocalized with 5HT immunoreactivity but was not detected elsewhere in the hindbrain (Fig. 1B-D and data not shown) consistent with endogenous Pet-1 expression (Hendricks et al., 1999). As expected, there was an absence of EYFP fluorescence in rhombomere 4 where 5HT neurons are not generated (Fig. 1A). Thus, the embryonic expression pattern of the ePet-EYFP line indicated that it could be used for identification and purification by flow cytometry of differentiating 5HT neurons from the rostral and caudal hindbrain.

We chose to profile gene expression at E12.5 when 5HT neurons are actively differentiating and cell migration and axon pathfinding are underway. At this developmental stage virtually all rostral 5HT neurons have differentiated (Pattyn et al., 2003). However, in the caudal hindbrain 5HT neuron differentiation is not yet complete at E12.5 and therefore the serotonergic cells at this stage are a mixture of postmitotic precursors and mature 5HT neurons. Rostral and caudal hindbrain domains were dissected from E12.5 ePet-EYFP embryos (Fig. 2*A*), dissociated with trypsin digestion and triturated in preparation for flow cytometry. For each sort (Fig. 2*B*), we also collected rostral YFP⁻ (R⁻) and caudal YFP⁻ (C⁻) reference cells, which comprise primarily neighboring hindbrain motoneurons and interneurons. The purity of sorted R⁺ and C⁺ neurons was analyzed by examining a



Figure 3. Unsupervised hierarchical clustering of serotonergic gene expression. *A*, Dendrogram showing unsupervised hierarchical clustering of R^+ , C^+ , R^- , and C^- gene expression profiles from the 12 arrays. Biological replicates show a high degree of reproducibility. *B*, Heat map displays eight distinct clusters of enriched gene expression in R^+ , C^+ , R^- , and C^- cell populations at E12.5. Each row represents the relative levels of expression for a single gene. The red or green color indicates high or low expression, respectively. Each column shows the expression profile for a single biological sample. Cluster I, Enriched gene expression in rostral 5HT and caudal 5HT neurons (R^+C^-); cluster II, enriched gene expression in rostral 5HT neurons (R^+R^-); cluster IV, enriched gene expression in caudal 5HT neurons (C^+); cluster VI, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-); cluster VII, enriched gene expression in caudal non-5HT neurons (R^-).

portion of the cells under fluorescence and phase contrast microscopy to determine the number of cells that were also YFP⁺ (Fig. 2*C*). Approximately 98% of rostral and caudal cells were YFP⁺ using our sorting parameters. We confirmed the purity of our sorted 5HT neurons by assaying for the expression of Fev (Pet-1) and Tph2, two genes whose expression in the CNS is restricted to 5HT neurons. Taqman real-time reverse transcription (RT)-PCR analyses of R⁺, C⁺, R⁻, and C⁻ total RNAs showed at least a 10-fold enrichment of Fev and Tph2 in R⁺ and C⁺ relative to R⁻ and C⁻ (Fig. 2*D*).

Probes (Fig. 2 *E*) were generated from 200,000 sorted rostral and caudal YFP⁺ cells and hybridized to Affymetrix 430 2.0 arrays. These hybridizations were used to generate present/absent (P/A) calls as described in the Materials and Methods. An annotated master list of expression signals and P/A calls for all 12 array profiles is presented in Dataset 1 (available at www.jneurosci.org as supplemental material). The data discussed in this publication have been deposited in the NCBI Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE19474 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE19474). We first analyzed our dataset to confirm that known

Table 1. Top 50 genes with enriched expression in R ⁺C ⁺ 5HT neurons (cluster I)

Affy ID	Fold change	Gene symbol	Gene title
1430105_at	19.9	1700042010Rik	RIKEN cDNA 1700042010 gene
1433434_at, 1433435_at	18.6, 7.1	AW551984	Expressed sequence AW551984
1460303_at, 1421867_at	14.8, 5.3	Nr3c1	Nuclear receptor subfamily 3, group C, member 1
1427038_at	10.9	Penk1	Preproenkephalin 1
1445546_at	10.8	AI844685	Expressed sequence AI844685
1445247_at	9.9	C530044C16Rik	RIKEN cDNA C530044C16 gene
1460578_at	9.6	Fgd5	FYVE, RhoGEF, and PH domain-containing 5
1421498_a_at	9.4	2010204K13Rik	RIKEN cDNA 2010204K13 gene
1433578_at	8.9	EG545758	Predicted gene, EG545758/solute carrier family 10 (sodium/bile acid cotransporter family), member 4
1436004_at	8.7	Usp27x	Ubiquitin-specific peptidase 27, X chromosome
1456108_x_at, 1418360_at, 1418360_at	8.5, 4.7, 4.2	Rnf112	Ring finger protein 112
1440891_at, 1435722_at	8.2, 6.2	Gria4	Glutamate receptor, ionotropic, AMPA4 (α 4)
1458230 at	7.1	_	_
1450344 a at	7.0	Ptger3	Prostaglandin E receptor 3 (subtype EP3)
1441330 at	6.9	Crb1	Crumbs homolog 1 (<i>Drosophila</i>)
1436772 at	6.7	_	_
1424842 a at	6.6	Arhgap24	Rho GTPase-activating protein 24
1455416 at	6.1	(130021120Rik	Riken cDNA (130021120 gene
1420955 at	5.9	Vsnl1	Visinin-like 1
1452981 at 1449563 at	5851	Cntn1	Contactin 1
1441779 at	5.6		
1456712 at 1455260 at	5544	Lorl	l igand-dependent nuclear recentor corepressor-like
1447707 s at 1452202 at	5439	Pde2a	Phosphodiesterase 2A cGMP-stimulated
1460097 at	53		
1428434 at	5.5	Zcchc12	Zinc finger CCHC domain-containing 12
1447669 s at	5.2	Gng4	Guanine nucleotide-hinding protein (G-protein) ~ 4
1/35030 c at	5.2	Honacam?	HEDACAM family member 2
1/17//1 at	5.1	Dinaic12	Dral (Hsp/0) homolog, subfamily (member 1)
1//70/6 at	J.1 // 0	Adam23	A dicintegrin and metallonentidase domain 23
1//1625_at	4.9	Rimhn?	RIMS-hinding protain 7
147025_at	4.9	Kindol	Kinse nonestalutic Clobe domain (KIND) containing 1
1420399_dl 1456793_st	4.0	7dbf2	Nildse Holicalalytic C-lobe dollariti (NiND)-collariting 1 Zing finger, DRE type, containing 2
1430705_dt	4.7	Such	Zinic ningel, DDI-type-containing Z
1434000_dl	4.7	JVZD Alcan 2 /Dalm 2	Syllaplic Vesicle giycopioleni z D
1441055_dl	4.4	AKapz/Palifiz	A KINASE (PKKA) dilchor protein 2/paraterninin 2/paraterninin 2/paraterninin 2/paraternining and a second
1419200_dl	4.5	FXYU/	Example Companies Contraining for transport regulator 7
1455664_dl	4.5	Syl1	Synaptologinin i C100 actives his disconsistent A10 (active disc)
1410/02_dt, 1420042_X_dt	4.3, 4.0	SIUGUIU Cama2d1	S IOU calcium-binding protein A IU (calpactin) Calcium channel veltage dependent - 2/S subvirit 1
1430702 at	4.2		
1429702_at	4.1	2900072GTTKIK	RIKEN CDNA 2900072GTT gene
1420622_a_at	4.0		Giutaminyi-peptide cyclotransterase (giutaminyi cyclase)
142077_at	4.0	23 1007 6G05 KIK	KIKEN CUNA 23 IUU/6005 gene
1433582_at	3.9	1 190002N 15KIK	RIKEN CUNA T 190002N 15 gene/nypotnetical protein LUC 100044725
1451046_at	3.9	LUC 100047651	Similar to FUG/Zinc finger protein, multitype i
141/398_at, 1448689_at	3.8, 3.6	Kras2	Kelated KAS viral (r-ras) oncogene homolog 2
1452114_s_at	3./	igfbp5	Insulin-like growth factor-binding protein 5
1433919_at	3./	Asb4	Ankyrin repeat and SUCS box-containing 4
1452936_at	3./	Crtaci	Cartilage acidic protein 1
1428221_at	3./	Kihdc8b	Keich domain-containing 8B
141/411_at	3.6	Nap115	Nucleosome assembly protein 1-like 5
1447933_at	3.5	Kif26a	Kinesin family member 26A

serotonergic genes were reproducibly detected. The arrays confirmed the enriched expression of 15 known serotonergic genes in R^+ and C^+ relative to R^- and C^- (Fig. 2*F*, *G*). Average signal intensities for these known 5HT neuron expressed genes ranged from 15,154 for probe set, 1435750_at, representing the GTP cyclohydrolase feedback regulator (Gchfr) to 335 for one of the probe sets, 1442676_at, that represents monoamine oxidase A (MaoA). We note, however, that our array studies failed to detect expression of some genes known to be expressed in 5HT neurons such as those encoding the htr1b receptor and α 1b adrenergic receptor. The reason for these discrepancies is unclear but may reflect immature levels of expression at E12.5. Nevertheless, the detection of the majority of the traditional 5HT neuron markers further indicates that the process of hindbrain dissociation and flow cytometry did not result in qualitative changes in the phenotype of these purified cells and therefore supports strong confidence in our approach for discovery of serotonergic gene expression.

We next analyzed the array data to assemble 5HT neuron gene expression profiles. 5HT neuron development and function depends on the activity of broadly expressed genes such as house-keeping genes as well as genes whose expression is highly selective for 5HT neurons such as Fev or TPH2. Thus, our first goal was to assemble a list of all genes expressed in E12.5 5HT neurons without consideration of their possible enrichment in R^+ and C^+ cell groups. We based our conservative estimate of the number of



Figure 4. Verification of 5HT neuron-enriched gene expression. *A*, *B*, Taqman RT-PCR verified 5HT neuron-enriched expression of transcription factors Rnf112, Zcchc12, Tox and RIKEN genes 2010204K13Rik, AW551984, and 1700042010Rik. *C*, Double-label immunohistochemistry for EYFP (brown) and *in situ* hybridization for AW551984 transcript (purple) verified the enriched expression of est AW551984 in 5HT neurons. *D*–*F*, Coimmunohistochemical staining of E12.5 neural tube confirmed FoxP1 (*E*) expression in YFP⁺ (*D*) 5HT neurons (*F*, overlay). Scale bars: *C*, 40 μm; *D*–*F*, 100 μm.

unique genes expressed in E12.5 5HT neurons on the number of probe sets in Dataset 1 (available at www.jneurosci.org as supplemental material) whose expression was reproducibly detected at a selected minimum threshold signal intensity level. Expression of a probe set was considered reproducibly detected if it was scored as present (P) in all three biological replicates of R^+ or C^+ profiles. The threshold signal intensity was set to the level of signal intensity for monoamine oxidase A probe set 1442676_at, whose mean expression level (335) was lowest of all probe sets for known serotonergic genes (Fig. 2G). Using these criteria, we estimated 12,559 probe sets were expressed in R⁺C⁺ cells, which corresponds to 8186 individual genes, 866 RIKEN cDNAs and 435 ESTs. A database of E12.5 5HT neuron expressed genes with respective mean signal intensity levels in R⁺ and C⁺ is available in Dataset 2 (available at www.jneurosci.org as supplemental material). A search of the Allen Institute Brain Atlas (Ng et al., 2009) revealed 250 genes with a TPH2-like expression pattern in the adult brain (supplemental Table S1, available at www.jneurosci. org as supplemental material). We detected expression of 155 of these genes in R⁺ and C⁺, indicating that many but not all TPH2like genes initiate expression during embryogenesis.

A major aim of this study was to identify new potential transcriptional determinants of 5HT neuron development. Therefore, we searched our list of 5HT neuron expressed genes according to protein molecular function and identified >800 genes encoding DNA binding proteins (supplemental Table S2, available at www.jneurosci.org as supplemental material). The complex innervation patterns of serotonergic axons that initiate around E12.5 led us to search for genes encoding axon pathfinding/cell adhesion molecules and 191 such genes were identified as expressed in R⁺ and C⁺ (supplemental Table S3, available at www.jneurosci.org as supplemental material). Finally, the neurochemically rich afferent input to 5HT neurons and the prominent role of the 5HT system in maintenance of homeostatic states prompted a search for genes encoding ion transport proteins, receptors and kinases. These searches uncovered 65 ion channel genes (supplemental Table S4, available at www.jneurosci.org as supplemental material), 118 solute carrier genes (supplemental Table S5, available at www. jneurosci.org as supplemental material), 38 G-protein-coupled receptors (supplemental Table S6, available at www.jneurosci.org as supplemental material), and 175 unique kinases (supplemental Table S7, available at www.jneurosci.org as supplemental material) expressed in R^+ and C^+ .

5HT neuron-enriched gene expression

We next sought to determine differentially expressed genes in our four groups of profiled cell populations. Using the ANOVA test, we found 1806 probe sets that were differentially expressed across the four groups based on the criteria described in the Material and Methods. Unsupervised hierarchical clustering was applied to reveal clusters of biological

samples and clusters of genes with similar expression patterns (Fig. 3). As shown in the dendrogram in Figure 3A, two distinct sample clusters were identified that correspond to the serotonergic and nonserotonergic cell groups we examined. Interestingly, the six serotonergic profiles sorted into two subclusters that correspond to the rostrocaudal origins of serotonin neurons, thus providing the first clear indication of large gene expression differences in rostral and caudal serotonin neurons. Not surprisingly, however, rostral and caudal serotonin neurons were more similar to each other than to nonserotonergic neurons from the same rostrocaudal level, while profiles of rostral and caudal nonserotonergic neurons were more similar to each other than to those of serotonergic neurons. Biological replicates for each of the different cell groups showed the highest similarities in gene expression patterns, thus further demonstrating the high reproducibility of our overall profiling method.

Hierarchical clustering of the genes revealed eight distinct gene expression clusters (I–VIII) that segregated according to serotonergic identity and rostrocaudal positions (Fig. 3*B*). Clusters I–V comprise unique profiles of ~800 transcripts differentially enriched in R^+ and C^+ serotonin neurons, while clusters VI–VIII comprise transcripts enriched in R^- and C^- nonserotonergic reference cell populations.

We systematically examined each of the five serotonergic clusters to identify prominent molecular features of 5HT neuron transcriptomes. Cluster I is comprised of 317 probe sets corresponding to 274 unique transcripts enriched in both rostral

Table 2. Gene ontology and pathway enrichment in R ⁺C ⁺ 5HT neurons

Biological process-enriched gene sets Lipid metabolic process 195/271 0.002807 8.72 × 10 $^{-6}$ 310 Caramide metabolic process 7/10 0.011107 0.03837 62 Calcium ion transport 12/24 0.011271 2.07 × 10 $^{-5}$ 765 Sphingolipid metabolic process 12/24 0.041981 0.0021 573 Proteolysis 7.8/162 1.87 × 10 $^{-5}$ 3.94 × 10 $^{-9}$ 561 Protein processing 19/42 0.3184 0.00265 246 G-protein-coupled receptor protein signaling pathway 101/290 0.000209 0.003268 557 Protein modification process 5/9 7.1 × 10 $^{-6}$ 0.682079 763 Sphingold metabolic process 5/9 7.1 × 10 $^{-6}$ 0.682079 763 Sphingold metabolic process 11/2 0.05149 0.00141 338 Gelular lipid metabolic process 11/2 0.052597 0.015825 74 Cation transport 17/2 0.05149 0.00141 338 Gelular lipid metabolic	Code	Gene set name	Size	R ⁺ Bon	C ⁺ Bon
310 Lipid metabolic process 19/271 0.002807 8.72 × 10 ⁻⁶ 125 Caramide metabolic process 7/10 0.011107 0.003837 62 Calcium ion transport 12/24 0.017271 0.0021 573 Proteipyiss 78/16 1.07 × 10 ⁻⁵ 0.0021 561 Protein processing 19/42 0.03184 0.00265 246 G-protein-coupled receptor protein signaling pathway 101/290 0.000209 0.002268 573 Protein motification process 5/9 7.1 × 10 ⁻⁶ 0.682079 566 Peptide metabolic process 5/9 7.1 × 10 ⁻⁶ 0.682079 573 Protein motification process 5/9 7.1 × 10 ⁻⁶ 0.682079 576 Peptide metabolic process 9/11 0.005257 0.00249 66 Celluin ripid metabolic process 116/212 0.05149 0.00141 338 Metal ion transport 53/102 1 0.000252 26 Ion transport 51/41066 0.134745 0.000252	Biological process-enriched ge	ne sets			
125 Ceramide metabolic process 7/10 0.01107 0.03837 62 Calcium ion transport 12/24 0.041981 2.07 × 10 ⁻⁵ 755 Sphinaglipi dre tabolic process 12/24 0.041981 0.0021 573 Proteolysis 78/162 1.87 × 10 ⁻⁵ 3.94 × 10 ⁻⁹ 561 Proteolysis 36/88 0.000265 0.00026 355 Membrane lipid metabolic process 36/88 0.000269 0.002261 577 Protein modification process 2/14/567 2.02 × 10 ⁻⁷ 5.86 × 10 ⁻⁵ 576 Protein modification process 9/11 0.055297 0.000249 0.000249 577 Protein modification process 9/11 0.055297 0.01825 168 0.019429 0.000429 0.000429 0.000429 0.00021 0.00021 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.00025 0.000141 0.000153 0.00025 0.000153 0	310	Lipid metabolic process	195/271	0.002807	8.72 $ imes$ 10 $^{-6}$
62 Galcium in transport $12/24$ 0.017271 2.07×10^{-5} 765 Sphingolipid metabolic process $72/4$ 0.041981 0.0021 573 Protein processing $78/162$ 1.87×10^{-5} 3.94×10^{-9} 561 Protein processing $78/68$ 0.008563 0.000209 0.003268 335 Membrane lipid metabolic process $3/67$ 7.05×10^{-7} 5.66×10^{-7} 5	125	Ceramide metabolic process	7/10	0.011107	0.003837
765 Sphinglight metabolic process 12/24 0.04181 0.0021 573 Proteolysis 78/162 1.87×10^{-5} 3.94×10^{-9} 335 Membrane lipid metabolic process $36/88$ 0.008263 0.000265 246 G-protein-coupled receptor protein signaling pathway $101/290$ 0.000209 0.003268 557 Protein modification process $214/657$ 2.02×10^{-7} 5.66×10^{-6} 456 Peptide metabolic process $9/11$ 0.055297 0.015825 168 Di-trivalent inorganic cation transport $17/29$ 0.152911 0.000249 86 Cellular lipid metabolic process $51/970$ 1 0.000235 74 Cation transport $53/102$ 1 0.000235 755 Protein metabolic process $51/4/1066$ 0.134745 0.000235 296 lon transport $53/102$ 1 0.000153 Cellular component-enriched gene sets $21/15$ 1.49×10^{-5} 0.04144 103 Intrinsic to membrane $27/5/866$ 2.79×10^{-5} 7.08×10^{-6} 192 <td>62</td> <td>Calcium ion transport</td> <td>12/24</td> <td>0.017271</td> <td>2.07 $imes$ 10 $^{-5}$</td>	62	Calcium ion transport	12/24	0.017271	2.07 $ imes$ 10 $^{-5}$
573 Proteolysis $78/162$ 1.87×10^{-5} 3.94×10^{-5} 561 Protein processing $19/42$ 0.03184 0.01963 335 Membrane lipid metabolic process $36/88$ 0.000256 0.000265 246 G-protein-coupled receptor protein signaling pathway $101/290$ 0.000209 0.003268 557 Protein modification process $5/9$ 7.1×10^{-6} 0.682079 763 Sphingoid metabolic process $9/11$ 0.055297 0.05126 168 D-, trivialen tinorganic cation transport $17/79$ 0.152911 0.0000429 86 Cellular lipid metabolic process 116/212 0.05149 0.001441 338 Metal ion transport $62/128$ 0.138503 7.68 \times 10^{-5} 74 Cation transport $62/128$ 0.138503 7.68 \times 10^{-5} 255 Protein metabolic process 514/1066 0.134745 0.000225 261 In transport $62/128$ 0.138503 7.68 \times 10^{-5} 755 Protein metabolic process 514/1066 0.134745 0.000225 261	765	Sphingolipid metabolic process	12/24	0.041981	0.0021
561 Protein processing 19/42 0.3184 0.01963 335 Membrane lipid metabolic process 36/88 0.008563 0.000265 246 G-protein-coupled receptor protein signaling pathway 101/290 0.000209 0.003268 557 Protein modification process 214/567 2.02 × 10 ⁻⁷ 5.86 × 10 ⁻⁶ 456 Peptide metabolic process 5/9 7.1 × 10 ⁻⁶ 0.682079 763 Splingid metabolic process 9/11 0.055297 0.015825 168 Di-, trivalent inorganic cation transport 17/29 0.152911 0.000026 74 Cation transport 5/12 0.05149 0.001331 74 Gation transport 5/14/1066 0.134745 0.000255 296 Ion transport 12/15 1.49 × 10 ⁻⁵ 0.04144 103 Intrinsic to membrane 237/164 2.76 × 10 ⁻¹¹ 3.1 × 10 ⁻¹ 92 Integral to plasma membrane 275/846 2.79 × 10 ⁻⁵ 7.08 × 10 ⁻⁶ 103 Intrinsic to membrane 237/84 0.001926 5.75 × 10 ⁻⁵ 103 Voltage	573	Proteolysis	78/162	1.87 $ imes$ 10 $^{-5}$	3.94 $ imes$ 10 $^{-9}$
335 Membrane lipid metabolic process 36/88 0.008563 0.000269 246 G-protein-coupled receptor protein signaling pathway 101/290 0.002209 0.003268 557 Protein modification process 214/557 2.02 × 10 ⁻⁷ 5.86 × 10 ⁻⁶ 456 Peptide metabolic process 5/9 7.1 × 10 ⁻⁶ 0.682079 763 Sphingoid metabolic process 9/11 0.055297 0.013825 168 Di, trivalent inorganic cation transport 17/29 0.152911 0.000429 86 Cellular lipid metabolic process 116/212 0.05149 0.001441 338 Metal ion transport 53/102 1 0.00025 74 Cation transport 62/128 0.138703 7.68 × 10 ⁻⁵ 255 Protein methabolic process 514/1066 0.134745 0.00025 266 Ion transport 75/161 1 0.0001533 Cellular component-enriched gene sets 12/15 1.49 × 10 ⁻⁵ 7.08 × 10 ⁻⁷ 32 Intergral to plasma membrane 387/1169	561	Protein processing	19/42	0.03184	0.01963
246G-protein-coupled receptor protein signaling pathway101/2900.0002090.003268557Protein modification process214/567 2.02×10^{-7} 5.86×10^{-6} 456Peptide metabolic process5/9 7.1×10^{-6} 0.682079763Sphingoid metabolic process9/110.0552970.015825168Di-, trivalent inorganic cation transport17/290.1529110.00042986Cellular ligid metabolic process15/10210.0002674Cation transport53/10210.00025755Protein metabolic process15/1/1080.138503 7.68×10^{-5} 555Protein metabolic process15/1/1060.1347450.00025296Ion transport75/16110.001533Cellular component-enriched gene sets2/121.49 \times 10^{-5}0.04144103Intrinsic to membrane275/8462.79 \times 10^{-5}7.08 \times 10^{-6}193Protein complex176/7036.86 \times 10^{-71}3.1 \times 10^{-1}92Integral to plasma membrane275/8462.79 \times 10^{-5}7.08 \times 10^{-6}102Exopeptidas activity3/2660.0001515.47 \times 10^{-5}103Altage-gated channel activity3/2660.001527.01 \times 10^{-9}104Ion transmembrane transporter activity3/260.001527.01 \times 10^{-9}102Exopeptidas activity3/260.001527.01 \times 10^{-9}103Intergal to plasma membrane movement of ions10	335	Membrane lipid metabolic process	36/88	0.008563	0.000265
557 Protein modification process $214/567$ 2.02×10^{-7} 5.86×10^{-6} 456 Peptide metabolic process $5/9$ 7.1×10^{-6} 0.682079 763 Sphingoid metabolic process $9/11$ 0.055297 0.015825 168 Di-, trivalent inorganic cation transport $17/29$ 0.152911 0.000429 86 Cellular lipid metabolic process $116/212$ 0.05149 0.001441 338 Metal ion transport $53/102$ 1 0.00036 74 Cation transport $62/128$ 0.138503 7.68×10^{-5} 296 Ion transport $53/102$ 1 0.000252 296 Io transport 7.68×10^{-5} 0.04144 103 Intrinsic to membrane $387/1169$ 2.76×10^{-5} 0.04144 103 Intrinsic to membrane $37/1164$ 2.79×10^{-5} 7.08×10^{-6} 193 Protein complex $12/15$ 1.49×10^{-5} 7.041×10^{-6} 193 Voltage-gated channel activity $32/66$ 0.000161 5.47×10^{-6} 104	246	G-protein-coupled receptor protein signaling pathway	101/290	0.000209	0.003268
456Peptide metabolic process $5/9$ 7.1×10^{-6} 0.682079 763Sphingoid metabolic process $9/11$ 0.055297 0.015825 168Di-, trivalent inorganic cation transport $17/29$ 0.152911 0.000429 86Cellular lipid metabolic process $116/212$ 0.5149 0.001441 338Metal ion transport $62/128$ 0.138503 7.68×10^{-5} 74Cation transport $62/128$ 0.138503 7.68×10^{-5} 555Protein metabolic process $514/1066$ 0.134745 0.0001533 Cellular component-enriched gene sets $12/15$ 1.49×10^{-5} 0.04144 103Intrinsic to membrane $387/1169$ 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 193Protein complex $7/7/703$ 6.86×10^{-7} 1.28×10^{-6} 102Exoperptidase activity $32/66$ 0.000161 5.47×10^{-6} 103AlTPase activity coupled to transmembrane movement of ions $10/22$ 0.00141 5.75×10^{-5} 30AlTPase activity coupled to transmembrane movement of ions $10/22$ 0.00161 5.47×10^{-5} 159Ion channel activity $5/70$ 0.001666 1 18Aminopeptidase activity $5/70$ 0.018666 1 18Arinopeptidase activity $2/0411$ $0.272c63$ 2.87×10^{-5} 314Serine-type endopeptidase activity	557	Protein modification process	214/567	$2.02 imes 10^{-7}$	5.86 $ imes$ 10 $^{-6}$
763Sphingoid metabolic process $9/11$ 0.055297 0.015825 168Di-, trivalent inorganic cation transport $17/29$ 0.15211 0.000429 86Cellular lipid metabolic process $116/212$ 0.05149 0.001441 338Metal ion transport $53/102$ 1 0.00036 74Cation transport $62/128$ 0.138503 7.68×10^{-5} 296Ion transport $75/161$ 1 0.001253 Cellular component-enriched gene sets $275/161$ 1 0.001533 221Voltage-gated calcium channel complex $12/15$ 1.49×10^{-5} 0.04144 103Intrinsic to membrane $38/7/169$ 2.76×10^{-111} 3.1×10^{-1} 92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 103Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 104103Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 102Exopeptidase activity $31/28$ 0.001926 5.75×10^{-5} 30Al?Base activity coupled to transmembrane movement of ions $10/22$ 0.04133 0.03688 159Ion channel activity $5/10$ 0.016866 1160Ion transmembrane transporter activity $9/10$ 1 0.000943 314Serine-type peptidase activity $9/10$ 1 0.000943 314Serine-type endopeptidase activity $2/27$ 0.88975 $8.$	456	Peptide metabolic process	5/9	$7.1 imes$ 10 $^{-6}$	0.682079
168Dir, trivalent inorganic cation transport17/290.1529110.00042986Cellular lipid metabolic process116/2120.051490.001441338Metal ion transport53/10210.0003674Cation transport62/1280.1385037.68 × 10 - 5555Protein metabolic process514/10660.1347450.000225296Ion transport75/16110.001533Cellular component-enriched gene sets221.49 × 10 - 50.04144103Intrinsic to membrane38/711692.76 × 10 - 113.1 × 10 - 192Integral to plasma membrane275/8462.79 × 10 - 57.08 × 10 - 6193Protein complex176/7036.86 × 10 - 71.28 × 10 - 6102Exopeptidase activity32/2660.0001615.47 × 10 - 6102Exopeptidase activity13/280.0019265.75 × 10 - 530AlTasea citivity coupled to transmembrane movement of ions10/220.0413030.03688159Ion channel activity57/100.0115392.22 × 10 - 7160Ion transmembrane transporter activity9/1010.000943314Serine-type peptidase activity5/100.016866118Aminopeptidase activity2/170.8899758.5 × 10 - 5312Garboxypeptidase activity2/1010.000943314Serine-type peptidase activity20/190.0538173.06 × 10 - 5314Serine	763	Sphingoid metabolic process	9/11	0.055297	0.015825
86 Cellular lipid metabolic process 116/212 0.05149 0.001441 338 Metal ion transport 53/102 1 0.00036 74 Cation transport 62/128 0.138503 7.68 × 10 ⁻⁵ 555 Protein metabolic process 514/1066 0.134745 0.00025 296 Ion transport 75/161 1 0.001533 Cellular component-enriched gene sets 12/15 1.49 × 10 ⁻⁵ 0.04144 103 Intrinsic to membrane 387/1169 2.76 × 10 ⁻¹¹ 3.1 × 10 ⁻¹ 92 Integral to plasma membrane 275/846 2.79 × 10 ⁻⁵ 7.08 × 10 ⁻⁶ 104 103 Protein complex 176/703 6.86 × 10 ⁻⁷ 1.28 × 10 ⁻⁶ 104 Exopeptidase activity 32/66 0.00161 5.47 × 10 ⁻⁶ 102 Exopeptidase activity coupled to transmembrane movement of ions 10/22 0.041303 0.03688 159 Ion channel activity 57/126 0.000252 7.01 × 10 ⁻⁹ 160 Ion transmembrane transporter activity <	168	Di-, trivalent inorganic cation transport	17/29	0.152911	0.000429
338Metal ion transport53/10210.0003674Cation transport $62/128$ 0.138503 7.68×10^{-5} 555Protein metabolic process $514/1066$ 0.134745 0.000225 296Ion transport $75/161$ 0.001533 Cellular component-enriched gene sets $12/15$ 1.49×10^{-5} 0.04144 103Intrinsic to membrane $387/1169$ 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 193Protein complex $176/703$ 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets $13/28$ 0.000126 5.75×10^{-5} 30Al'Pase activity $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity $31/28$ 0.001926 5.75×10^{-5} 30Al'Pase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $9/10$ 1 0.000943 314Serine-type peridase activity $9/10$ 1 0.000943 314Serine-type endopeptidase activity $2/37$ 0.388975 8.5×10^{-5} 55Catio transmembrane transporter activity $0/10$ 0.03825 0.000041 314Serine-type endopeptidase activity $2/37$ 0.388975 8.5×10^{-5} 55 <td>86</td> <td>Cellular lipid metabolic process</td> <td>116/212</td> <td>0.05149</td> <td>0.001441</td>	86	Cellular lipid metabolic process	116/212	0.05149	0.001441
74Cation transport62/1280.1385037.68 \times 10 $^{-5}$ 555Protein metabolic process514/10660.1347450.000225296Ion transport75/16110.001533Cellular component-enriched gene sets232Voltage-gated calcium channel complex12/151.49 \times 10 $^{-5}$ 0.04144103Intrinsic to membrane387/11692.76 \times 10 $^{-11}$ 3.1 \times 10 $^{-1}$ 92Integral to plasma membrane275/8462.79 \times 10 $^{-5}$ 7.08 \times 10 $^{-6}$ 193Protein complex176/7036.86 \times 10 $^{-7}$ 1.28 \times 10 $^{-6}$ 102Exopeptidase activity32/660.0001615.47 \times 10 $^{-6}$ 102Exopeptidase activity13/280.0019265.75 \times 10 $^{-5}$ 30AlPase activity coupled to transmembrane movement of ions10/220.0413030.03688159Ion channel activity5/100.0115392.22 \times 10 $^{-7}$ 50Carboxypeptidase activity4/120.0335250.041814201Neuropeptide hormone activity5/100.016866118Aminopeptidase activity9/1010.000943314Serine-type endopetidase activity22/370.8899758.5 \times 10 $^{-5}$ 55Cation transmebrane transporter activity100/1940.0538173.06 \times 10 $^{-7}$ 50RAB pathway9/106.33 \times 10 $^{-7}$ 0.00080164No.51 nathway9/100.001630.00845 <td>338</td> <td>Metal ion transport</td> <td>53/102</td> <td>1</td> <td>0.00036</td>	338	Metal ion transport	53/102	1	0.00036
555Protein metabolic process514/10660.1347450.000225296Ion transport75/16110.001533Cellular component-enriched gene sets222Voltage-gated calcium channel complex12/15 1.49×10^{-5} 0.04144103Intrinsic to membrane387/1169 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane275/846 2.79×10^{-5} 7.08 \times 10^{-6}193Protein complex176/703 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets $32/66$ 0.000161 5.47×10^{-6} 303Voltage-gated channel activity32/660.000161 5.47×10^{-6} 5.75×10^{-5} 304ATPase activity coupled to transmembrane movement of ions10/220.0413030.03688159Ion channel activity57/1260.0002527.01 \times 10^{-9}160Ion transmembrane transporter activity9/120.0335250.041814201Neuropeptidase activity9/1010.000943314Serine-type petidase activity2/370.889975 8.5×10^{-5} 312Serine-type petidase activity2/370.889975 8.5×10^{-5} 55Caton transmembrane transporter activity20/370.889975 8.5×10^{-5} 312Serine-type petidase activity2/370.889975 8.5×10^{-5} 55Caton transmembrane transporter activity00/1940.053817 3.06×10^{-6} 64	74	Cation transport	62/128	0.138503	$7.68 imes10^{-5}$
296Ion transport $75/161$ 10.001533Cellular component-enriched gene sets232Voltage-gated calcium channel complex $12/15$ 1.49×10^{-5} 0.04144 103Intrinsic to membrane387/1169 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane275/846 2.79×10^{-5} 7.08×10^{-6} 193Protein complex176/703 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets32/660.000161 5.47×10^{-6} 393Voltage-gated channel activity $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity13/280.01926 5.75×10^{-5} 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.0413030.03688159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $9/10$ 0.016866 118Aminopeptidase activity $5/10$ 0.016866118Aminopeptidase activity $20/41$ 0.277263 2.87×10^{-5} 312Serine-type eptidase activity $20/41$ 0.277263 2.87×10^{-5} 55Cation transmembrane transporter activity $20/10$ 0.053817 3.06×10^{-6} Ganonical pathway-enriched gene sets 50^{9} RAB pathway $9/10$ 6.33×10^{-7} 0.000801	555	Protein metabolic process	514/1066	0.134745	0.000225
Cellular component-enriched gene sets232Voltage-gated calcium channel complex $12/15$ 1.49×10^{-5} 0.04144 103Intrinsic to membrane $387/1169$ 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 193Protein complex $176/703$ 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets $13/28$ 0.00161 5.47×10^{-6} 102Exopeptidase activity $13/28$ 0.001926 5.75×10^{-5} 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50 Carboxypeptidase activity $9/10$ 1 0.00943 314 Serine-type peptidase activity $9/10$ 1 0.00943 312 Serine-type endopeptidase activity $22/37$ 0.889975 8.5×10^{-5} 55 Cation transmembrane transporter activity $100/194$ 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801	296	lon transport	75/161	1	0.001533
232Voltage-gated calcium channel complex $12/15$ 1.49×10^{-5} 0.04144 103Intrinsic to membrane $387/1169$ 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 193Protein complex $176/703$ 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets 393 Voltage-gated channel activity $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity $13/28$ 0.001926 5.75×10^{-5} 30 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50Carboxypeptidase activity $9/10$ 1 0.000943 18Aminopeptidase activity $9/10$ 1 0.000943 314Serine-type peptidase activity $22/37$ 0.889975 8.5×10^{-5} 55Cation transmembrane transporter activity $100/194$ 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801	Cellular component-enriched o	iene sets			
103Intrinsic to membrane $387/1169$ 2.76×10^{-11} 3.1×10^{-1} 92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 193Protein complex $176/703$ 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity $32/66$ 0.000161 5.47×10^{-5} 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50Carboxypeptidase activity $4/12$ 0.033525 0.041814 201Neuropeptide hormone activity $5/10$ 0.016866 118Aminopeptidase activity $9/10$ 1 0.000943 314Serine-type petidase activity $22/37$ 0.889975 8.5×10^{-5} 55Cation transmembrane transporter activity $100/194$ 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801 509RAB pathway $9/10$ 6.33×10^{-7} 0.000801 0.00845	232	Voltage-gated calcium channel complex	12/15	$1.49 imes 10^{-5}$	0.04144
92Integral to plasma membrane $275/846$ 2.79×10^{-5} 7.08×10^{-6} 193Protein complex $176/703$ 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets 393 Voltage-gated channel activity $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity $13/28$ 0.001926 5.75×10^{-5} 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50Carboxypeptidase activity $4/12$ 0.033525 0.041814 201Neuropeptide hormone activity $5/10$ 0.016866 118Aminopeptidase activity $26/41$ 0.277263 2.87×10^{-5} 312Serine-type peptidase activity $22/37$ 0.889975 8.5×10^{-5} 55Cation transmembrane transporter activity $100/194$ 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801	103	Intrinsic to membrane	387/1169	$2.76 imes 10^{-11}$	$3.1 imes 10^{-13}$
193Protein complex176/703 6.86×10^{-7} 1.28×10^{-6} Molecular function-enriched gene sets393Voltage-gated channel activity $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity $13/28$ 0.001926 5.75×10^{-5} 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50Carboxypeptidase activity $4/12$ 0.033525 0.041814 201Neuropeptide hormone activity $5/10$ 0.016866 118Aminopeptidase activity $9/10$ 1 0.000943 314Serine-type peptidase activity $22/37$ 0.889975 8.5×10^{-5} 312Serine-type endopeptidase activity $20/77$ 0.38177 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801	92	Integral to plasma membrane	275/846	$2.79 imes 10^{-5}$	$7.08 imes10^{-6}$
Molecular function-enriched gene sets 393 Voltage-gated channel activity 32/66 0.000161 5.47×10^{-6} 102 Exopeptidase activity 13/28 0.001926 5.75×10^{-5} 30 ATPase activity coupled to transmembrane movement of ions 10/22 0.041303 0.03688 159 Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160 Ion transmembrane transporter activity 94/245 0.011539 2.22×10^{-7} 50 Carboxypeptidase activity 4/12 0.033525 0.041814 201 Neuropeptide hormone activity 5/10 0.016866 1 18 Aminopeptidase activity 9/10 1 0.000943 314 Serine-type peptidase activity 22/37 0.889975 8.5×10^{-5} 312 Serine-type endopeptidase activity 22/37 0.889975 8.5×10^{-5} 55 Cation transmembrane transporter activity 100/194 0.053817 3.06×10^{-6} 609 RAB pathway 9/10 6.33×10^{-7} 0.000801 454 Nos1 nathway 15/20 0.00163	193	Protein complex	176/703	$6.86 imes 10^{-7}$	$1.28 imes10^{-6}$
393Voltage-gated channel activity $32/66$ 0.000161 5.47×10^{-6} 102Exopeptidase activity $13/28$ 0.001926 5.75×10^{-5} 30ATPase activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50Carboxypeptidase activity $4/12$ 0.033525 0.041814 201Neuropeptide hormone activity $5/10$ 0.016866 118Aminopeptidase activity $9/10$ 1 0.000943 314Serine-type peptidase activity $26/41$ 0.277263 2.87×10^{-5} 312Serine-type endopeptidase activity $22/37$ 0.889975 8.5×10^{-5} 55Cation transmembrane transporter activity $10/194$ 0.053817 3.06×10^{-6} 6anonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801 454Nos1 nathwayNos1 nathway $15/20$ 0.00163 0.00845	Molecular function-enriched q	ene sets			
102Exopptidase activity13/280.001926 5.75×10^{-5} 30ATPase activity coupled to transmembrane movement of ions10/220.0413030.03688159Ion channel activity57/1260.0002527.01 \times 10^{-9}160Ion transmembrane transporter activity94/2450.0115392.22 \times 10^{-7}50Carboxypeptidase activity4/120.0335250.041814201Neuropeptide hormone activity5/100.016866118Aminopeptidase activity9/1010.000943314Serine-type peptidase activity26/410.2772632.87 \times 10^{-5}312Serine-type endopeptidase activity22/370.8899758.5 × 10^{-6}55Cation transmembrane transporter activity100/1940.0538173.06 × 10^{-6}6anonical pathway-enriched gene sets509RAB pathway9/106.33 × 10^{-7}0.000801454Nos1 nathway15/200.0010630.00845	393	Voltage-gated channel activity	32/66	0.000161	5.47 $ imes$ 10 $^{-6}$
30ATP as activity coupled to transmembrane movement of ions $10/22$ 0.041303 0.03688 159Ion channel activity $57/126$ 0.000252 7.01×10^{-9} 160Ion transmembrane transporter activity $94/245$ 0.011539 2.22×10^{-7} 50Carboxypeptidase activity $4/12$ 0.033525 0.041814 201Neuropeptide hormone activity $5/10$ 0.016866 118Aminopeptidase activity $9/10$ 1 0.00943 314Serine-type peptidase activity $26/41$ 0.277263 2.87×10^{-5} 312Serine-type endopeptidase activity $22/37$ 0.889975 8.5×10^{-5} 55Cation transmembrane transporter activity $100/194$ 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801 454Nos1 nathwayNos1 nathway $15/20$ 0.00163 0.00845	102	Exopeptidase activity	13/28	0.001926	$5.75 imes$ 10 $^{-5}$
159Ion channel activity57/1260.000252 7.01×10^{-9} 160Ion transmembrane transporter activity94/2450.011539 2.22×10^{-7} 50Carboxypeptidase activity4/120.0335250.041814201Neuropeptide hormone activity5/100.016866118Aminopeptidase activity9/1010.000943314Serine-type peptidase activity26/410.277263 2.87×10^{-5} 312Serine-type endopeptidase activity22/370.889975 8.5×10^{-5} 55Cation transmembrane transporter activity100/1940.053817 3.06×10^{-6} Canonical pathway-enriched gene sets509RAB pathway9/10 6.33×10^{-7} 0.000801454Nos1 nathway15/200.0010630.00845	30	ATPase activity coupled to transmembrane movement of ions	10/22	0.041303	0.03688
160Ion transmembrane transporter activity94/2450.011539 2.22×10^{-7} 50Carboxypeptidase activity4/120.0335250.041814201Neuropeptide hormone activity5/100.016866118Aminopeptidase activity9/1010.000943314Serine-type peptidase activity26/410.2772632.87 \times 10^{-5}312Serine-type endopeptidase activity22/370.889975 8.5×10^{-5} 55Cation transmembrane transporter activity100/1940.053817 3.06×10^{-6} Canonical pathway-enriched gene sets509RAB pathway9/10 6.33×10^{-7} 0.000801454Nos1 nathway15/200.0011630.00845	159	lon channel activity	57/126	0.000252	$7.01 imes 10^{-9}$
50Carboxypeptidase activity4/120.0335250.041814201Neuropeptide hormone activity5/100.016866118Aminopeptidase activity9/1010.000943314Serine-type peptidase activity26/410.2772632.87 × 10 $^{-5}$ 312Serine-type endopeptidase activity22/370.8899758.5 × 10 $^{-5}$ 55Cation transmembrane transporter activity100/1940.0538173.06 × 10 $^{-6}$ Canonical pathway-enriched gene sets509RAB pathway9/106.33 × 10 $^{-7}$ 0.000801454Nos1 nathway15/200.0011630.00845	160	lon transmembrane transporter activity	94/245	0.011539	$2.22 imes 10^{-7}$
201 Neuropeptide hormone activity 5/10 0.016866 1 18 Aminopeptidase activity 9/10 1 0.000943 314 Serine-type peptidase activity 26/41 0.277263 2.87 × 10 ⁻⁵ 312 Serine-type endopeptidase activity 22/37 0.889975 8.5 × 10 ⁻⁵ 55 Cation transmembrane transporter activity 100/194 0.053817 3.06 × 10 ⁻⁶ Canonical pathway-enriched gene sets 509 RAB pathway 9/10 6.33 × 10 ⁻⁷ 0.000801 454 Nos1 nathway 15/20 0.00163 0.00845	50	Carboxypeptidase activity	4/12	0.033525	0.041814
18 Aminopeptidase activity 9/10 1 0.000943 314 Serine-type peptidase activity 26/41 0.277263 2.87×10^{-5} 312 Serine-type endopeptidase activity 22/37 0.889975 8.5×10^{-5} 55 Cation transmembrane transporter activity 100/194 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway 9/10 6.33×10^{-7} 0.000801 454 Nos1 nathway 15/20 0.00163 0.00845	201	Neuropeptide hormone activity	5/10	0.016866	1
314 Serine-type peptidase activity 26/41 0.277263 2.87 × 10 ⁻⁵ 312 Serine-type endopeptidase activity 22/37 0.889975 8.5 × 10 ⁻⁵ 55 Cation transmembrane transporter activity 100/194 0.053817 3.06 × 10 ⁻⁶ Canonical pathway-enriched gene sets 509 RAB pathway 9/10 6.33 × 10 ⁻⁷ 0.000801 454 Nos1 nathway 15/20 0.001063 0.00845	18	Aminopeptidase activity	9/10	1	0.000943
312 Serine-type endopeptidase activity 22/37 0.889975 8.5×10^{-5} 55 Cation transmembrane transporter activity 100/194 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway 9/10 6.33×10^{-7} 0.000801 454 Nos1 nathway 15/20 0.001063 0.00845	314	Serine-type peptidase activity	26/41	0.277263	$2.87 imes 10^{-5}$
55 Cation transmembrane transporter activity 100/194 0.053817 3.06×10^{-6} Canonical pathway-enriched gene sets 509 RAB pathway 9/10 6.33×10^{-7} 0.000801 454 Nos1 nathway 15/20 0.001163 0.00845	312	Serine-type endopeptidase activity	22/37	0.889975	8.5×10^{-5}
Canonical pathway-enriched gene sets 509 RAB pathway $9/10$ 6.33×10^{-7} 0.000801 454 Nos1 pathway $15/20$ 0.00163 0.00845	55	Cation transmembrane transporter activity	100/194	0.053817	3.06×10^{-6}
S09 RAB pathway 9/10 6.33 × 10 ⁻⁷ 0.000801 454 Nos1 pathway 15/20 0.001063 0.00845	Canonical pathway-enriched g	ene sets			
454 Not natway 15/20 0.00163 0.0085	509	RAB pathway	9/10	6.33×10^{-7}	0.000801
	454	Nos1 pathway	15/20	0.001063	0.00845
249 HSA00600 sphingolipid metabolism 18/31 0.00138 0.022235	249	HSA00600 sphingolipid metabolism	18/31	0.00138	0.022235
244 HSA00564 alvcerophospholipid metabolism 32/68 0.002839 0.000696	244	HSA00564 glycerophospholipid metabolism	32/68	0.002839	0.000696

Bon, Bonferroni-corrected *p* value.

and caudal 5HT neurons (supplemental Table S8, available at www.jneurosci.org as supplemental material). Only 13 of these genes have been shown by the Allen Institute to have a TPH2-like expression pattern in the adult brain. Further filtering of the cluster I list to exclude additional known serotonergic genes revealed 250 new genes with severalfold enrichment in R^+ and C^+ cells, thus validating our approach for discovery of 5HT neuron gene expression in the developing hindbrain (Table 1). Several of these potential new markers of developing 5HT neurons have well defined functions in other neural and non-neural cell types, while the function of others have not been elucidated.

Because of our interest in genes controlling 5HT neuron development, we focused our enrichment verification studies primarily on genes encoding known and putative transcriptional regulators. The genes we selected for confirmation spanned the full range of probe set signal intensities (1350–15,000) (supplemental Table S8, available at www.jneurosci.org as supplemental material). Taqman RT-PCR (Fig. 4A) confirmed the highly enriched expression of the zinc finger factor, Zcchc12, which is also known as Smad-interacting zinc finger protein (Sizn1) and whose known sequence variants are associated with mental retardation (Cho et al., 2008b). Zcchc12 is an X-linked gene that has been shown to promote cholinergic transmitter phenotype by stimulating bone morphogenetic protein-dependent regulation of choline acetyltransferase and vesicular acetylcholine transporter genes in basal forebrain cholinergic neurons (Cho et al., 2008a). These known functions raise the possibility that Zcchc12 also regulates serotonergic neuron neurochemical properties. Rnf112 (also known as Zfp179 or Znf179) is thought to encode a zinc finger transcription factor (Seki et al., 1999). We verified Rnf112 enrichment in rostral and caudal 5HT neurons by Taqman RT-PCR (Fig. 4A). The Rnf112 gene maps within the common chromosomal 17p11.2 duplicated region that is responsible for Potocki-Lupski syndrome (PLS) (Kimura et al., 1997). This syndrome is characterized by neurodevelopmental and behavioral phenotypes including anxiety and autism spectrum features (Potocki et al., 2007). We confirmed expression of some other genes exhibiting more modest enrichment in R⁺ and C⁺. For example, Tox (thymocyte selection-associated high mobility group box) is a gene required for T-cell maturation and is also strongly expressed in the developing cingulate and motor cortex of the E16 mouse brain (Mühlfriedel et al., 2007). We found a

Table 3. Top genes with enriched expression in R ⁺ (cluster II) and R ⁺R ⁻ (cluster III)

Affy ID	Fold change	Gene symbol	Gene title
R ⁺ -enriched genes			
1425804_at	29.7	Hmx2	H6 homeobox 2
1420444_at	27.1	Slc22a3	Solute carrier family 22 (organic cation transporter), member 3
1437339 s at, 1451406 a at	8.9, 6.1	Pcsk5	Proprotein convertase subtilisin/kexin type 5
1449031 at	8.3	Cited1	Cbp/p300-interacting transactivator with Glu/Asp-rich C-terminal domain 1
 1452065_at	7.9	Vstm2a	V-set and transmembrane domain-containing 2A
1456512 at	7.2	Pdzrn4	PDZ domain-containing RING finger 4
1425083 at	6.8	Otor	Otoraplin
1422052 at 1455365 at	5.7. 4.8	Cdb8	Cadherin 8
1450047 at	53	Hs6st2	Henaran sulfate 6-0-sulfotransferase 2
1419719 at	5.1	Gabrb1	GABA, receptor, subunit <i>B</i> 1
1426621 a at	49	Pnn2r2h	Protein phosphatase 2 (formerly 2A) regulatory subunit B (PR 52) B isoform
1436662 at	4 5	Sorcs1	VPS10 domain recentor protein SORCS 1
1436137 at	43	Slc6a17	Solute carrier family 6 (neurotransmitter transnorter) member 17
1440545 at	4.2	ENSMUSG0000075319	Predicted gene ENSMUSG0000075319
1440455 at 1456600 at	40.36	(amk2n1	Calcium/calmodulin-dependent protein kinace II inhibitor 1
1450708 at	3.0	Kirrol3	Kin of IRRE-like 3 (Droconbila)
1432720_at	2.0	Hmv2	H6 homoobox 2
1422150_dt	2.0	CXIIII Lynd1	Luc /Dlaur domain containing 1
1431309_d_dl 1436713+	2.0 2.0	Lypu I Sle6a1E	Ly0/Fidul u011dill-C011dillilly I Soluto carrier family 6 (neurotransmitter transporter) member 15
1420712_dl	2.0 2.0.2.2		Solute (affer failing o (neurotransinitter transporter), member 15
1423331_dl, 1434113_dl	3.8, 3.3	Callis	
1420778_at	3./	 (================================	— Crawlastanastin, and brad like densing autoralysing 2
1449979_a_at	3.6	Spock3	Sparc/osteonectin, cwcv, and kazai-like domains proteoglycan 3
1440425_at	3.6		
1429390_at	3.5	Acp12	Acid phosphatase-like 2
1459214_at	3.4		—
1438729_at	3.4	Sox1	SRY-box-containing gene 1
R + R -enriched genes		_	
1418868_at	18.3	En2	Engrailed 2
1438009_at	11.1	Hist1h2ab/Hist1h2ac	Histone cluster 1
1437996_s_at, 1455471_at	8.4, 6.6	00012D20Rik	RIKEN cDNA 1500012D20 gene
1418618_at	7.2	En1	Engrailed 1
1418666_at	4.5	Ptx3	Pentraxin-related gene
1456127_at	4.5	Cnpy1	Canopy 1 homolog (zebrafish)
1455620_at	3.6	EG628779	Predicted gene, EG628779
1442558_at	3.4	ENSMUSG0000072792	Predicted gene, ENSMUSG00000072792
1451888_a_at	3.0	Odz4	Odd Oz/ten-m homolog 4 (<i>Drosophila</i>)
1447676_x_at, 1425560_a_at	2.8, 2.7	S100a16	S100 calcium-binding protein A16
1454178_at	2.6	2610027F03Rik	RIKEN cDNA 2610027F03 gene
1434458_at	2.5	Fst	Follistatin
1452968_at	2.4	Cthrc1	Collagen triple helix repeat-containing 1
1451983_at	2.2	lrx1	Iroquois-related homeobox 1 (<i>Drosophila</i>)
1427252_at	2.1	Dmrtb1	DMRT-like family B with proline-rich C-terminal, 1
1439557_s_at	2.1	Ldb2	LIM domain-binding 2
1435917_at	1.9	Ociad2	OCIA domain-containing 2
1426298 at	1.9	Irx2/L0C100045612	Iroquois-related homeobox 2 (<i>Drosophila</i>)
	1.8	_	
	1.8	Tmem53	Transmembrane protein 53
1435297 at	1.8	Gid2	Gap junction protein, $\delta 2$
1425530 a at	1.7	Stx3	Syntaxin 3
1418502 a at	1.7	0xr1	Oxidation resistance 1
1424133 at	1.5	Tmem98	Transmembrane protein 98

3.0-fold enrichment of Tox expression in R^+ and C^+ by array analysis and a similar level of enrichment was also detected by Taqman assays (Fig. 4*A*). RIKEN cDNA 1700042O10RIK, showed a 20-fold enrichment in R^+C^+ by array detection and 30-fold and 150-fold enrichment in R^+ and C^+ , respectively, by Taqman RT-PCR (Fig. 4*B*). Interestingly, 1700042O10RIK encodes a noncoding RNA of unknown function whose gene is embedded in the dopa decarboxylase gene but on opposite strands. This finding raises the intriguing hypothesis that 1700042O10RIK RNA is a novel regulator of ddc transcription in 5HT neurons by a *cis*-antisense mechanism. We also verified ex-

pression of other genes whose functions cannot be predicted by homology comparisons. RIKEN cDNA 2010204K13RIK encodes a predicted single transmembrane 83 amino acid protein and was enriched 10-fold in both R^+ and C^+ . In addition, we confirmed the strong expression of EST AW551984 by both Taqman RT-PCR (Fig. 4*B*) and double-label *in situ* hybridization (Fig. 4*C*). Confirmation of the 5HT neuron-specific expression of these uncharacterized protein-coding genes suggests novel proteins carry out functions specifically in 5HT neurons. FoxP1, a forkhead domain transcription factor, is required for motoneuron diversity and ultimately the development of spinal cord motor



Figure 5. Verification of rostral 5HT neuron-enriched HD gene expression. *A*, Taqman RT-PCR confirmed enriched expression of Hmx2, Hmx3, and Pou3f1 homeodomain genes in rostral (R⁺) but not caudal (C⁺) 5HT neurons. *B–D*, Double-label *in situ* hybridization (blue) and immunohistochemistry for EYFP (brown) confirmed expression of Hmx2 (*B*) and Hmx3 (*C*) in E12.5 rostral 5HT neurons. *D*, Hmx2 expression was maintained in rostral 5HT neurons at E16.5. *E*, Taqman RT-PCR verification of enriched En1 and En2 gene expression in E12.5 rostral 5HT neurons (R⁺) as well as non-5HT cells (R⁻ and C⁻) but not caudal 5HT neurons (C⁺). *F*, *In situ* hybridization for En2 at E12.5 shows a broad domain of expression on either side of the MHB. Immunohistochemical staining with a pan-engrailed antibody (red) detected En1 and En2 proteins in EYFP⁺ (green) 5HT neurons in rhombomere 1 at E12.5. *G*, En1/2 protein expression persisted in rostral 5HT neurons at E14.5. Scale bars: *B*, *C*, *G*, 50 µm; *D*, *H*, 100 µm; *F*, 500 µm.

circuitry (Rousso et al., 2008). We found a 2.1-fold enrichment of FoxP1 in R⁺ and C⁺. Immunohistochemical detection of FoxP1 indicated that FoxP1 protein was expressed by a large number of both rostral and caudal 5HT neurons at E12.5 (Fig. 4*D*–*F*). Altogether, the verified highly enriched expression of these genes in R⁺ and C⁺ suggests new candidate regulators of 5HT neuron development.

Gene ontology and pathway enrichment in 5HT neurons

The distinct gene expression profiles detected in 5HT neurons versus reference nonserotonergic cell types suggest 5HT neurons may selectively use particular signaling and biological pathways. We used our recently developed parametric approach (Wang et al., 2008) based on mixed linear models to search for enrichment of sets of genes that operate together in a common signaling pathways or are associated with GO categories: molecular function, biological process, and cellular component. We queried gene sets for canonical pathways and gene ontology terms in the MSigDB collection. Because many gene sets were examined, to control for the rate of false-positive findings by chance, we adjusted nominal p values using Bonferroni correction. We identified highly significant enrichment of numerous gene sets for canonical pathways and GO categories in R⁺C⁺ profiles relative to reference R^-C^- profiles (Table 2; see Dataset 3, available at www.jneurosci.org as supplemental material), which suggests that 5HT neurons perform a variety of specialized functions. Enrichment of numerous gene sets associated with peptide processing is consistent with the known peptidergic activity of some 5HT neurons and further reveals the molecules that may be required for use of these peptides as serotonergic signals. A large number of gene sets associated with ion transport and G-protein-coupled

receptor pathways may reflect the complexity of afferent signaling systems regulating 5HT neuron activity and is consistent with the idea that cell surface channels and receptors are a major determinant of cell type heterogeneity in the nervous system (Doyle et al., 2008).

Finally, our analyses identified nine significantly enriched gene sets associated with lipid and specifically sphingolipid (SL) metabolism in R⁺ and C⁺ compared to reference groups R⁻ and C⁻ (Table 2). SLs have been suggested to influence many aspects of nervous system development including neuronal proliferation, differentiation and axonal growth, and synaptic vesicle exocytosis (Colombaioni and Garcia-Gil, 2004; Darios et al., 2009). Ceramide has been shown to promote axonal growth and branching in cultured hippocampal neurons (Schwarz and Futerman, 1997). We speculate that serotonergic enrichment of SL metabolic pathways during the period of 5HT neuron maturation may be required to support the exuberant and complex axonogenesis and collateralization that must occur for proper development of this transmitter system.

Rostral 5HT neuron transcriptome landscape

The segregation of several hundred R⁺ or C⁺ expressed genes into four additional clusters (clusters II–IV) suggested previously unrecognized deep molecular heterogeneity in these two groups of embryonic 5HT neurons. We, therefore, examined these clusters individually to identify molecular signatures that distinguish rostral and caudal 5HT neurons.

Cluster II (Table 3) is comprised of 94 probe sets corresponding to 84 unique transcripts enriched in R^+ (supplemental Table S9, available at www.jneurosci.org as supplemental material). This list revealed the highly enriched expression of two genes,

Table 4. Top genes with enriched expression in C⁺ (cluster IV) and C⁺C⁻ (cluster V)

Any iz Fou change dene symbol dene fille	
C ⁺ -enriched genes	
1441429 at 20.3 Irs4 Insulin receptor substrate 4	
1442724 at 15.6 Dlk1 δ -like 1 homolog (<i>Drosophila</i>)	
1455436 at 13.0 Diras2 DIRAS family GTP-binding RAS-like 2	
141858 a at 11.9 Mlf1 Mveloid leukemia factor 1	
1457733 at 97 — — —	
1457765 s. at 96 Nr3c1 Nuclear recentor subfamily 3. group (member 1	
120250 a at 93 Arhoeß Rho quanter nucleatide exchange factor (GEE) 3	
1/2/25/2012 Annual An	
146042 at 7 7 3110047D20Bik DiKSL10047D20Bik	
$1/100 - 02_a t$ 7.7 $5 - 100 - 120 tink - 1100 - 1100 - 1100 - 120 gene - 140000 c a t 7.4 7.4 7.4 7.10 + 120 - 100$	
14620 - 4 61	
1449200_{al} 0.1 — — — — — — — — — — — — — — — — — — —	
1416/30_dt 3.0 IIII III/0UUDIII-TERASING III/III/0UE	
14300/9_at 5.3 0/4503/51110k NIKEN (UNA 04503/511) (SEE	
1437 606_41 5.3 DCU25092 CDINA Sequence DCU25092	
1441256_dt 5.2 AF529109 (DINA Sequence AF529109	
1433/8/_at 5.2 Nelli NEL-IKE I (CIICKEN)	
1423836_at 5.1 Zrp503 Zinc ringer protein 503	
1448125_at 5.0 Kit2 Ras-like without CAAX 2	
142/122_at 4.9 Copg2as2 Coatomer protein complex, subunit γ 2, antisense 2	
143982/_at 4.9 Adamts12 A disintegrin-like and metallopeptidase (reprolysin type) w	with thrombospondin type 1 motif, 12
1428765_at 4.7 Meg3 Maternally expressed 3	
1417217_at 4.6 Magel2 Melanoma antigen, family L, 2	
1435513_at 4.4 Htr2c 5-Hydroxytryptamine (serotonin) receptor 2C	
1449465_at 4.4 Reln Reelin	
1427123_s_at 4.2 Copg2as2 Coatomer protein complex, subunit γ 2, antisense 2	
C + C -enriched genes	
1418415_at 68.0 Hoxb5 Homeobox B5	
1441070_at, 1429019_s_at 46.0, 5.5 Hoxb3 Homeobox B3	
1458622_at, 1455426_at 39.7, 4.7 Hoxa5 Homeobox A5	
1423756_s_at 33.8 Hoxc4 Homeobox C4	
1449368_at, 1421841_at 23.1, 7.2 Hoxd3 Homeobox D3	
1428429_at, 1452421_at 19.7, 4.2 Hoxa3 Homeobox A3	
1451277_at 17.6 Hoxc5 Homeobox C5	
1439885_at 16.9 Hoxb6 Homeobox B6	
1457966_at 12.5 Hoxb4 Homeobox B4	
1438042_at 10.9 Al448005 Expressed sequence Al448005	
144543_at 10.1 — —	
1440177_at, 1434818_at, 1455299_at 9.8, 8.8, 6.9 Ttr Transthyretin	
1460379_at 8.4 Hoxb2 Homeobox B2	
1428026_at 8.1 Hoxa4 Homeobox A4	
1416783_at 7.7 Tac1 Tachykinin 1	
1460214_at 7.6 Dcn Decorin	
1450209_at 6.9 Shox2 Short stature homeobox 2	
1420401_a_at 6.9 Hoxa2 Homeobox A2	
1456229_at 5.7 0610040B09Rik RIKEN cDNA 0610040B09 gene	
1458470_at 5.4 A930038C07Rik RIKEN cDNA A930038C07 gene	
1416561_at 4.9 Gad1 Glutamic acid decarboxylase 1	
1430596 s at 4.9 Sorl1 Sortilin-related receptor, LDLR class A repeats-containing	
1460693 a at 4.2 Hoxb7/Hoxb8 Homeobox B7/homeobox B8	
1451761 at 3.9 — —	
1451461_a_at 3.9 — —	

Hmx2 (Nkx5.2) and Hmx3 (Nkx5.1), encoding related homeodomain proteins in R^+ with little or no expression detected in C^+ . Taqman RT-PCR confirmed the enriched expression of both Hmx2 (80-fold) and Hmx3 (120-fold) in R^+ (Fig. 5*A*). *In situ* hybridization double-label immunohistochemistry at E12.5 demonstrated that Hmx2 (Fig. 5*B*) marked all rostral 5HT neurons, while Hmx3 expression was observed in a subpopulation of rostral 5HT neurons (Fig. 5*C*). Hmx2 expression was maintained at E16.5 (Fig. 5*D*), while Hmx3 transcript was detectable at a lower level at E14.5 (data not shown). The expression of these genes provides a molecular signature of serotonergic neurons in the rostral hindbrain. Verification of Pou3f1, a POU homeodomain transcription factor, indicated enriched expression to a lesser extent than the Hmx genes in \mathbb{R}^+ (Fig. 5*A*).

Cluster III comprises 27 probe sets that correspond to 25 unique transcripts enriched in both R⁺ and R⁻ cells (Table 3; supplemental Table S10, available at www.jneurosci.org as supplemental material). Of particular interest in this list are the engrailed homeodomain transcription factor genes, En1 and En2, which have been extensively studied for their multiple roles in nervous system development including establishment of the midbrain-hindbrain boundary, cerebellum development, axonal

guidance, and dopamine neuron development and survival (Joyner, 1996; Simon et al., 2004). Taqman RT-PCR confirmed their enrichment in R⁺ as well as R⁻ and C^{-} reference cell populations but not C^{+} (Fig. 5E). In situ hybridization for En2 at E12.5 showed a broad domain of expression that spanned both sides of the midhindbrain boundary (MHB) (Fig. 5F). Postmitotic rostral 5HT neurons have migrated from the ventricular zone by E12.5 and were situated in the En2+ region below the MHB. Immunohistochemical detection with a pan-engrailed antibody (Davis et al., 1991) showed strong and persistent expression of En1/En2 proteins in a subset of postmitotic rostral 5HT neurons in rhombomere 1 (r1) at least through E14.5 (Fig. 5G,H). These findings raise the possibility that engrailed genes play cell-autonomous roles in the differentiation and maintenance of rostral 5HT neurons.

Caudal 5HT neuron transcriptome landscape

We next examined clusters IV and V to identify transcripts enriched in caudal 5HT neurons. Cluster IV comprises 300 probe sets, which correspond to 270 unique transcripts and 29 RIKEN cDNAs enriched in C⁺ neurons (Table 4; supplemental Table S11, available at www. jneurosci.org as supplemental material). We identified several imprinted genes, Dlk1, Meg3, Magel2, and Copg2as2, each with severalfold-enriched expression in

 C^+ . However, unlike the Hmx and En genes, whose expression was overwhelmingly enriched in rostral 5HT neurons, these C^+ enriched genes also showed significant but less enrichment in R^+ cells (Dataset 2, available at www.jneurosci.org as supplemental material). These genes are members of three distinct imprinted domains present on different chromosome and thus raise the possibility that stringent regulation of gene dosage is important for proper 5HT neuron development and function. Further examination of our databases revealed an additional 70 probe sets corresponding to 43 unique imprinted genes showing expression in rostral and caudal 5HT neurons (supplemental Table S12, available at www.jneurosci.org as supplemental material). Only three of these, Ancient, Magel2, Ddc, are reported in the Allen Brain Library list of genes with a TPH2-like expression pattern in the adult mouse brain.

Cluster V represents an additional group of serotonergic genes whose expression was enriched in both C⁺ and C⁻ cells. This cluster comprises 146 probe sets, which corresponds to 113 unique genes and 9 RIKEN cDNAs (Table 4; supplemental Table S13, available at www.jneurosci.org as supplemental material). A striking feature of this profile is the numerous Hox paralogues whose expression was enriched in C⁺ and C⁻ up to 70-fold relative to R⁺ and R⁻. Our array studies detected highly enriched expression of 14 Hox genes and their cofactors Meis1 and Meis 2 in C⁺, whereas there was little or no expression of these Hox genes in R⁺ (Dataset 2, available at www.jneurosci.org as supple-



Figure 6. Verification of Hox gene expression in caudal 5HT neurons. *A*–*C*, Taqman RT-PCR confirmed the expression of Hox3 (*A*), Hox4 (*B*), and Hox5 (*C*) paralogues in caudal (C⁺) but not rostral (R⁺) 5HT neurons. *D*–*L*, Immunohistochemical staining for the Hox cofactors, Meis 1 and Meis 2, and Hox proteins. *D*–*F*, Meis1 and Meis2 (*E*) were detected in caudal 5HT neurons (*D*) with a pan-anti-Meis antibody (*F*, overlay). *G*–*I*, HoxC4 protein (*H*) was detected in caudal 5HT neurons (*G*, *I*, overlay). *J*–*L*, HoxA3 protein (*K*) was detected in most caudal 5HT neurons (*J*) at E12.5 (*L*, overlay). Scale bars: *D*–*L*, 50 μm.

mental material). Hox genes are well known for their early roles in patterning morphological identities of embryonic structures along the anterior-posterior body axis (Pearson et al., 2005), and more recently they have been implicated in repression of serotonergic fate in rhombomere 4 (Pattyn et al., 2003) and specifying spinal motor-neuron pool identity (Dasen et al., 2005). We verified enrichment of Hox3, Hox4, and Hox5 paralogues by Taqman RT-PCR (Fig. 6A-C). Expression of Meis1 and Meis2 (Fig. 6D-F), HoxC4 (Fig. 6G-I), and HoxA3 (Fig. 6J-L) proteins was confirmed by immunohistochemistry in caudal 5HT neurons. At E12.5, Meis1/2 and HoxA3 expression spanned the caudal hindbrain and marked most caudal 5HT neurons. HoxC4 expression extended from the spinal cord and into the most posterior hindbrain thus marking only subset of caudal 5HT neurons. The expression of Hox genes was also reported in array studies of differentiated 5HT neurons derived from a rhesus monkey embryonic stem cell line (Bethea et al., 2009). Together, these findings suggest Hox proteins and their cofactors play important roles in the maturation of postmitotic caudal 5HT neurons.

Gene ontology and differential pathway enrichment in rostral and caudal 5HT neurons

We compared gene set enrichment in R⁺ versus C⁺ expression profiles to further explore the potential functional and metabolic differences between rostral and caudal 5HT neurons. Numerous

Table 5. Gene ontology	and pathway enrichment in R ⁻	⁺ versus C ⁺ 5HT neurons
------------------------	--	--

Code	Gene set name	Size	Bon
R ⁺ molecular function-enriched gene sets			
346	Substrate-specific transmembrane transporter activity	152/308	0.02889313
271	Protein kinase activity	129/264	0.00560058
347	Substrate-specific transporter activity	167/347	0.00245254
163	Kinase activity	156/342	0.00065897
328	Small GTPase regulator activity	21/64	0.00779472
C ⁺ biological process-enriched gene sets			
62	Calcium ion transport	15/24	0.00074155
168	Di-, trivalent inorganic cation transport	18/29	0.00021683
800	Transport	392/703	0.00019125
246	G-protein-coupled receptor protein signaling pathway	114/290	3.6497 $ imes$ 10 $^{-5}$
C ⁺ molecular function-enriched gene sets			
18	Aminopeptidase activity	8/10	0.00490194
174	Lipid kinase activity	8/11	0.03140293
38	Calcium channel activity	19/30	0.01250318
118	GTPase regulator activity	77/122	0.00713664
279	Protein serine threonine kinase activity	116/189	2.405 $ imes$ 10 $^{-5}$
168	Ligand-gated channel activity	17/32	0.00144691
384	Transmembrane transporter activity	174/338	0.01154298
188	Metal ion transmembrane transporter activity	66/131	0.00658676

Bon, Bonferroni-corrected *p* value.

gene sets were differentially enriched in R^+ and C^+ neurons, including those associated with intracellular signaling pathways, GPCR pathways, channel activity, integrin pathways, axon guidance, and ion transport. Gene sets associated with several metabolic pathways were also differentially enriched in either R^+ or C^+ , thus further indicating major differences in R^+ and C^+ gene expression and further supporting possibility of significant physiological differences in these serotonergic cell types (Table 5, see Dataset 4, available at www.jneurosci.org as supplemental material for complete list).

Discussion

This study reports the isolation of postmitotic 5HT neurons from the embryonic mouse hindbrain by flow cytometry and the use of these cells to profile 5HT neuron gene expression. Our array studies detected expression of ~9000 unique gene products in E12.5 5HT neurons with enriched expression of nearly 800 of these genes. The number of unique genes we detected as expressed in 5HT neurons corresponds strikingly well to the ~10,000 unique genes that are expressed in a single Aplysia 5HT interneuron. Few of the most highly enriched 5HT expressed genes, however, were common to these two kinds of 5HT neurons (Moroz et al., 2006). We identified 250 genes whose expression was comparably enriched in both rostral and caudal 5HT neurons and therefore these genes represent potential new markers of developing 5HT neurons. Several of these genes encode proteins with well defined functions in other neural and nonneural cell types. We also detected enriched expression of noncoding RNAs and genes encoding potential proteins whose functions are not predictable from primary structure. Furthermore, gene set enrichment analysis identified potential signaling and biological pathways in 5HT neurons that may support specialized functional roles of these cells. Our findings provide an unprecedented knowledge of the expressed genetic architecture of 5HT neurons and continued verification will sharpen our understanding of this architecture.

5HT neurons are anatomically and functionally heterogeneous but the molecular mechanisms that determine these distinctions are obscure because of a lack of comprehensive expression profiling of these cells. Our findings demonstrate deep molecular and biological pathway distinctions between neurons that give rise to the ascending and descending serotonergic subsystems. Previous immunohistochemical studies have reported the differential expression of a small number of genes encoding various neuropeptides, receptors and the transmitters GABA and glutamate in adult 5HT neurons (Chan-Palay et al., 1978; Hökfelt et al., 1978, 2000; Belin et al., 1983; Day et al., 2004; Lacoste et al., 2006). The Allen Institute identified 248 genes with a Tph2-like expression pattern in adults, but it is not known whether these genes are differentially expressed in developing rostral and caudal 5HT neurons. Here we demonstrate the power of whole-genome profiling of purified embryonic 5HT neurons by identifying ~500 genes with major expression differences between developing rostral and caudal 5HT neurons. Many of these genes encode various types of transcription factors, although we also detected differential expression of genes encoding ion channels, intracellular signaling factors, and axonal guidance cues. Rostral and caudal 5HT neurons also display differential enrichment of gene sets that suggest different biological pathways operate in these two anatomically defined populations of 5HT neurons. These findings substantiate the concept derived from genetic fate mapping of 5HT progenitors (Jensen et al., 2008) that despite their common neurotransmitter character distinct developmental programs generate 5HT neurons in the rostral and caudal hindbrain.

The differential expression of numerous homeodomain (HD) genes, including En1, En2, Hmx2, and Hmx3 in rostral 5HT neurons and several Hox in caudal 5HT neurons raises the possibility that different intrinsic transcriptional cascades comprising different HDs may operate in developing postmitotic 5HT neurons. Hmx2 and Hmx3 are required for inner ear development and differentiation of specific hypothalamic neuronal cell types (Wang et al., 2004) but they have not been investigated for a role in 5HT neuron development. En1, 2 are required in a redundant manner for 5HT neuron development (Simon et al., 2005). As En expression was reported to be undetected in 5HT neurons these findings were interpreted as indicating a cell non-autonomous role for En1, 2 in 5HT neuron development. However, more recent intersectional/subtractive genetic cell fate

mapping studies have demonstrated that a pool of En⁺ progenitors in r1 give rise to all 5HT neurons that populate the adult B4, B6, and B7 raphe nuclei as well as some 5HT neurons in the B5 and B8 median raphe and B9 nuclei (Jensen et al., 2008). In addition, our array, RT-qPCR and immunohistochemical verification findings presented here indicated highly enriched expression of En1 and En2 in an anterior subset of postmitotic rostral 5HT neurons in r1. Together, these findings strongly suggest that rather than playing a cell nonautonomous role, En1/2 genes have intrinsic roles in rostral 5HT neurons.

Our array and verification studies showed highly enriched expression of Hmx2 and Hmx3 in rostral 5HT neurons with no detectable expression of these genes in caudal 5HT neurons. Furthermore, Hox expression was detected in caudal 5HT neurons but not in rostral ones. Thus, rostral 5HT neurons can be defined as an Hmx⁺ subtype and caudal 5HT neurons as a Hox⁺ subtype. Our findings also define two rostral postmitotic 5HT neuron subtypes (Hmx⁺En⁺ and Hmx⁺En⁻) based on the differential expression of En1/2 hence corroborating evidence (Jensen et al., 2008) for serotonergic heterogeneity even greater than suggested by simple rostral and caudal anatomical distinctions. An important question to address experimentally is whether or not En1/2 and the other HD expression constitute an HD code that is required in specific subsets of postmitotic 5HT neurons to direct and maintain heterogeneous programs of serotonergic differentiation, cell body migration, axonal trajectories, or electrophysiological properties.

Our transcriptome studies have identified many previously unrecognized serotonergic genes with potential roles in disease pathogenesis. Of particular interest are the cell adhesion genes, *Cntnap2*, *Nrxn1*, and *Cdh10*, which we have shown here to be expressed in 5HT neurons and whose common and rare genetic variants have been associated with autism susceptibility (Arking et al., 2008; Kim et al., 2008; Wang et al., 2009). These genes can now be investigated to determine what role they play in 5HT neurons and whether their disrupted function results in specific disease endophenotypes. Thus, our databases provide a unique bioinformatics resource to help determine serotonergic expression of genes identified in human psychiatric genome association and linkage studies.

Interestingly, we found expression of 43 different imprinted genes in rostral and caudal 5HT neurons (supplemental Table 12, available at www.jneurosci.org as supplemental material), of which 19 were enriched in 5HT neurons. There are 131 currently known mouse imprinted genes including snoRNAs and miRNAs (http://www.har.mrc.ac.uk/). Many imprinted genes are expressed in the brain and are thought to play critical roles in neurodevelopmental disorders such as autism (Wilkinson et al., 2007). Serotonergic expression of imprinted genes, however, has not been investigated and thus our findings raise the intriguing concept that maternal versus paternal gene expression dosage is important for normal serotonergic function and serotonergic modulation of behavior. An interesting example is Magel2, a paternally imprinted gene that encodes a member of MAGE domain family of proteins (Barker and Salehi, 2002) that is nearly fivefold enriched in C⁺. Magel2 and necdin, another MAGE domain imprinted gene, are located near one another in the chromosomal 15q11-q13 region, which when deleted from the paternal allele results in Prader-Willi syndrome (PWS) and when deleted from the maternal allele results in Angelman syndrome (Horsthemke and Wagstaff, 2008). Among the many behavioral and physiological defects present in children with PWS are severe respiratory abnormalities including frequent apneas and irregular rhythms (Nixon and Brouillette, 2002). Recent studies in mice have shown that Necdin is also expressed in developing and adult 5HT neurons (Zanella et al., 2008) and as shown here (Dataset 2, available at www.jneurosci.org as supplemental material) at least as early as E12.5. Loss of Necdin function in mice results in defects in 5HT neuron axonal outgrowth and transmitter vesicles (Lee et al., 2005; Zanella et al., 2008). In addition, Necdin^{-/-} mice have respiratory deficits that resemble those in PWS (Ren et al., 2003; Zanella et al., 2008) and is consistent with our finding of severe respiratory deficits in 5HT deficient Pet-1^{-/-} neonates (Erickson et al., 2007). Similarly, Magel $2^{-/-}$ mice have serotonergic deficits (Mercer et al., 2009) and therefore combined loss of function of Necdin and Magel2 in 5HT neurons may contribute to the respiratory deficits seen in PWS. Further support for an important role of Magel2 in 5HT neuron development is the additional behavioral similarities of Pet-1^{-/-} and Magel2^{-/-} mice, including increased anxiety in novel environments and maternal behavior defects (Mercer and Wevrick, 2009; Mercer et al., 2009). The latter abnormality is likely to account for the poor survival of neonates born to Magel2^{-/-} dams and is consistent with recent findings from our laboratory using $Pet-1^{-/-}$ females (Lerch-Haner et al., 2008) and confirmed with TPH2 nulls (Alenina et al., 2009) that brain 5HT is critical for reproductive success. Finally, the PWS imprinted region contains several other imprinted and nonimprinted genes. Examination of our array database indicates serotonergic expression of additional genes in this region including the imprinted genes, MKRN3, SNRF/ SNRPN, UBE3a, and the biallelically expressed GABRB3 gene. Together, these findings suggest expression of the 15q11-q13 region may play an important role in 5HT neuron development and its altered dosage in these cells may contribute to neurodevelopmental disorders.

In conclusion, we have identified numerous potential new determinants of 5HT neuron development and function including several homeodomain-encoding genes whose differential expression offers a molecular classification of 5HT neuron subtypes. Our findings provide a wealth of new knowledge and experimentally testable hypotheses about the genetic networks that generate serotonin neuron subtypes and the potential roles of serotonergic genes in disease pathogenesis.

References

- Alenina N, Kikic D, Todiras M, Mosienko V, Qadri F, Plehm R, Boyé P, Vilianovitch L, Sohr R, Tenner K, Hörtnagl H, Bader M (2009) Growth retardation and altered autonomic control in mice lacking brain serotonin. Proc Natl Acad Sci U S A 106:10332–10337.
- Ansorge MS, Hen R, Gingrich JA (2007) Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 7:8–17.
- Arking DE, Cutler DJ, Brune CW, Teslovich TM, West K, Ikeda M, Rea A, Guy M, Lin S, Cook EH, Chakravarti A (2008) A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet 82:160–164.
- Barker PA, Salehi A (2002) The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67:705–712.
- Beck SG, Pan YZ, Akanwa AC, Kirby LG (2004) Median and dorsal raphe neurons are not electrophysiologically identical. J Neurophysiol 91:994–1005.
- Belin MF, Nanopoulos D, Didier M, Aguera M, Steinbusch H, Verhofstad A, Maitre M, Pujol JF (1983) Immunohistochemical evidence for the presence of gamma-aminobutyric acid and serotonin in one nerve cell. A study on the raphe nuclei of the rat using antibodies to glutamate decarboxylase and serotonin. Brain Res 275:329–339.
- Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57:289–300.

- Bethea CL, Reddy AP, Pedersen D, Tokuyama Y (2009) Expression profile of differentiating serotonin neurons derived from rhesus embryonic stem cells and comparison to adult serotonin neurons. Gene Expr Patterns 9:94–108.
- Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28:264–278.
- Chan-Palay V, Jonsson G, Palay SL (1978) Serotonin and substance P coexist in neurons of the rat's central nervous system. Proc Natl Acad Sci U S A 75:1582–1586.
- Cho G, Lim Y, Zand D, Golden JA (2008a) Sizn1 is a novel protein that functions as a transcriptional coactivator of bone morphogenic protein signaling. Mol Cell Biol 28:1565–1572.
- Cho G, Bhat SS, Gao J, Collins JS, Rogers RC, Simensen RJ, Schwartz CE, Golden JA, Srivastava AK (2008b) Evidence that SIZN1 is a candidate X-linked mental retardation gene. Am J Med Genet A 146A:2644–2650.
- Colombaioni L, Garcia-Gil M (2004) Sphingolipid metabolites in neural signalling and function. Brain Res Brain Res Rev 46:328-355.
- Darios F, Wasser C, Shakirzyanova A, Giniatullin A, Goodman K, Munoz-Bravo JL, Raingo J, Jorgacevski J, Kreft M, Zorec R, Rosa JM, Gandia L, Gutiérrez LM, Binz T, Giniatullin R, Kavalali ET, Davletov B (2009) Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. Neuron 62:683–694.
- Dasen JS, Tice BC, Brenner-Morton S, Jessell TM (2005) A Hox regulatory network establishes motor neuron pool identity and target-muscle connectivity. Cell 123:477–491.
- Davis CA, Holmyard DP, Millen KJ, Joyner AL (1991) Examining pattern formation in mouse, chicken and frog embryos with an En-specific antiserum. Development 111:287–298.
- Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF, Campeau S (2004) Differential expression of 5HT-1A, alpha 1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, gammaaminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J Comp Neurol 474:364–378.
- Doyle JP, Dougherty JD, Heiman M, Schmidt EF, Stevens TR, Ma G, Bupp S, Shrestha P, Shah RD, Doughty ML, Gong S, Greengard P, Heintz N (2008) Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 135:749–762.
- Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863–14868.
- Erickson JT, Shafer G, Rossetti MD, Wilson CG, Deneris ES (2007) Arrest of 5HT neuron differentiation delays respiratory maturation and impairs neonatal homeostatic responses to environmental challenges. Respir Physiol Neurobiol 159:85–101.
- Gargaglioni LH, Bícegoa KC, Branco LG (2008) Brain monoaminergic neurons and ventilatory control in vertebrates. Respir Physiol Neurobiol 164:112–122.
- Hendricks T, Francis N, Fyodorov D, Deneris ES (1999) The ETS domain factor Pet-1 is an early and precise marker of central 5-HT neurons and interacts with a conserved element in serotonergic genes. J Neurosci 19:10348–10356.
- Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B, Silver J, Weeber EJ, Sweatt JD, Deneris ES (2003) Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron 37:233–247.
- Hodges MR, Tattersall GJ, Harris MB, McEvoy SD, Richerson DN, Deneris ES, Johnson RL, Chen ZF, Richerson GB (2008) Defects in breathing and thermoregulation in mice with near-complete absence of central serotonin neurons. J Neurosci 28:2495–2505.
- Hökfelt T, Ljungdahl A, Steinbusch H, Verhofstad A, Nilsson G, Brodin E, Pernow B, Goldstein M (1978) Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptaminecontaining neurons in the rat central nervous system. Neuroscience 3:517–538.
- Hökfelt T, Arvidsson U, Cullheim S, Millhorn D, Nicholas AP, Pieribone V, Seroogy K, Ulfhake B (2000) Multiple messengers in descending serotonin neurons: localization and functional implications. J Chem Neuroanat 18:75–86.

- Holmes A (2008) Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 32:1293–1314.
- Horsthemke B, Wagstaff J (2008) Mechanisms of imprinting of the Prader-Willi/Angelman region. Am J Med Genet A 146A:2041–2052.
- Jacob J, Ferri AL, Milton C, Prin F, Pla P, Lin W, Gavalas A, Ang SL, Briscoe J (2007) Transcriptional repression coordinates the temporal switch from motor to serotonergic neurogenesis. Nat Neurosci 10:1433–1439.
- Jensen P, Farago AF, Awatramani RB, Scott MM, Deneris ES, Dymecki SM (2008) Redefining the serotonergic system by genetic lineage. Nat Neurosci 11:417–419.
- Joyner AL (1996) Engrailed, Wnt and Pax genes regulate midbrain-hindbrain development. Trends Genet 12:15–20.
- Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, Shen Y, Lally E, Weiss LA, Najm J, Kutsche K, Descartes M, Holt L, Braddock S, Troxell R, Kaplan L, Volkmar F, Klin A, Tsatsanis K, Harris DJ, Noens I, et al. (2008) Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 82:199–207.
- Kimura T, Arakawa Y, Inoue S, Fukushima Y, Kondo I, Koyama K, Hosoi T, Orimo A, Muramatsu M, Nakamura Y, Abe T, Inazawa J (1997) The brain finger protein gene (ZNF179), a member of the RING finger family, maps within the Smith-Magenis syndrome region at 17p11.2. Am J Med Genet 69:320–324.
- Kocsis B, Varga V, Dahan L, Sik A (2006) Serotonergic neuron diversity: identification of raphe neurons with discharges time-locked to the hip-pocampal theta rhythm. Proc Natl Acad Sci U S A 103:1059–1064.
- Lacoste B, Riad M, Descarries L (2006) Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus. Eur J Neurosci 23:2947–2958.
- Lee S, Walker CL, Karten B, Kuny SL, Tennese AA, O'Neill MA, Wevrick R (2005) Essential role for the Prader-Willi syndrome protein necdin in axonal outgrowth. Hum Mol Genet 14:627–637.
- Le François B, Czesak M, Steubl D, Albert PR (2008) Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55:977–985.
- Leonardo ED, Hen R (2006) Genetics of affective and anxiety disorders. Annu Rev Psychol 57:117–137.
- Lerch-Haner JK, Frierson D, Crawford LK, Beck SG, Deneris ES (2008) Serotonergic transcriptional programming determines maternal behavior and offspring survival. Nat Neurosci 11:1001–1003.
- Lillesaar C, Tannhäuser B, Stigloher C, Kremmer E, Bally-Cuif L (2007) The serotonergic phenotype is acquired by converging genetic mechanisms within the zebrafish central nervous system. Dev Dyn 236:1072–1084.
- Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151–162.
- Mason P (2001) Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions. Annu Rev Neurosci 24:737–777.
- Mercer RE, Wevrick R (2009) Loss of magel2, a candidate gene for features of Prader-Willi syndrome, impairs reproductive function in mice. PLoS ONE 4:e4291.
- Mercer RE, Kwolek EM, Bischof JM, van Eede M, Henkelman RM, Wevrick R (2009) Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output gene Magel2. Am J Med Genet B Neuropsychiatr Genet 150B:1085–1099.
- Moroz LL, Edwards JR, Puthanveettil SV, Kohn AB, Ha T, Heyland A, Knudsen B, Sahni A, Yu F, Liu L, Jezzini S, Lovell P, Iannucculli W, Chen M, Nguyen T, Sheng H, Shaw R, Kalachikov S, Panchin YV, Farmerie W, et al. (2006) Neuronal transcriptome of *Aplysia*: neuronal compartments and circuitry. Cell 127:1453–1467.
- Mühlfriedel S, Kirsch F, Gruss P, Chowdhury K, Stoykova A (2007) Novel genes differentially expressed in cortical regions during late neurogenesis. Eur J Neurosci 26:33–50.
- Ng L, Bernard A, Lau C, Overly CC, Dong HW, Kuan C, Pathak S, Sunkin SM, Dang C, Bohland JW, Bokil H, Mitra PP, Puelles L, Hohmann J, Anderson DJ, Lein ES, Jones AR, Hawrylycz M (2009) An anatomic gene expression atlas of the adult mouse brain. Nat Neurosci 12:356–362.
- Nixon GM, Brouillette RT (2002) Sleep and breathing in Prader-Willi syndrome. Pediatr Pulmonol 34:209–217.
- Pattyn A, Vallstedt A, Dias JM, Samad OA, Krumlauf R, Rijli FM, Brunet JF, Ericson J (2003) Coordinated temporal and spatial control of motor neuron and serotonergic neuron generation from a common pool of CNS progenitors. Genes Dev 17:729–737.

- Pearson JC, Lemons D, McGinnis W (2005) Modulating Hox gene functions during animal body patterning. Nat Rev Genet 6:893–904.
- Potocki L, Bi W, Treadwell-Deering D, Carvalho CM, Eifert A, Friedman EM, Glaze D, Krull K, Lee JA, Lewis RA, Mendoza-Londono R, Robbins-Furman P, Shaw C, Shi X, Weissenberger G, Withers M, Yatsenko SA, Zackai EH, Stankiewicz P, Lupski JR (2007) Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am J Hum Genet 80:633–649.
- Prasad HC, Zhu CB, McCauley JL, Samuvel DJ, Ramamoorthy S, Shelton RC, Hewlett WA, Sutcliffe JS, Blakely RD (2005) Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci U S A 102: 11545–11550.
- Reimers M, Carey VJ (2006) Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol 411:119– 134.
- Ren J, Lee S, Pagliardini S, Gérard M, Stewart CL, Greer JJ, Wevrick R (2003) Absence of Ndn, encoding the Prader-Willi syndrome-deleted gene necdin, results in congenital deficiency of central respiratory drive in neonatal mice. J Neurosci 23:1569–1573.
- Rousso DL, Gaber ZB, Wellik D, Morrisey EE, Novitch BG (2008) Coordinated actions of the forkhead protein Foxp1 and Hox proteins in the columnar organization of spinal motor neurons. Neuron 59:226–240.
- Schwarz A, Futerman AH (1997) Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J Neurosci 17:2929– 2938.
- Scott MM, Wylie CJ, Lerch JK, Murphy R, Lobur K, Herlitze S, Jiang W, Conlon RA, Strowbridge BW, Deneris ES (2005) A genetic approach to access serotonin neurons for in vivo and in vitro studies. Proc Natl Acad Sci U S A 102:16472–16477.
- Seki N, Hattori A, Muramatsu M, Saito T (1999) cDNA cloning of a human brain finger protein, BFP/ZNF179, a member of the RING finger protein family. DNA Res 6:353–356.
- Simon HH, Thuret S, Alberi L (2004) Midbrain dopaminergic neurons: control of their cell fate by the engrailed transcription factors. Cell Tissue Res 318:53–61.
- Simon HH, Scholz C, O'Leary DD (2005) Engrailed genes control develop-

mental fate of serotonergic and noradrenergic neurons in mid- and hindbrain in a gene dose-dependent manner. Mol Cell Neurosci 28:96–105.

- Smyth GK (2005) Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor (Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds), pp 397–420. New York: Springer.
- Sodhi MS, Sanders-Bush E (2004) Serotonin and brain development. Int Rev Neurobiol 59:111–174.
- Sugino K, Hempel CM, Miller MN, Hattox AM, Shapiro P, Wu C, Huang ZJ, Nelson SB (2006) Molecular taxonomy of major neuronal classes in the adult mouse forebrain. Nat Neurosci 9:99–107.
- Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, Salyakina D, Imielinski M, Bradfield JP, Sleiman PM, Kim CE, Hou C, Frackelton E, Chiavacci R, Takahashi N, Sakurai T, Rappaport E, Lajonchere CM, Munson J, Estes A, et al. (2009) Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 459:528–533.
- Wang L, Zhang B, Wolfinger RD, Chen X (2008) An integrated approach for the analysis of biological pathways using mixed models. PLoS Genet 4:e1000115.
- Wang W, Grimmer JF, Van De Water TR, Lufkin T (2004) Hmx2 and Hmx3 homeobox genes direct development of the murine inner ear and hypothalamus and can be functionally replaced by *Drosophila* Hmx. Dev Cell 7:439–453.
- Wilkinson LS, Davies W, Isles AR (2007) Genomic imprinting effects on brain development and function. Nat Rev Neurosci 8:832–843.
- Ye W, Shimamura K, Rubenstein JLR, Hynes MA, Rosenthal A (1998) FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 93:755–766.
- Zanella S, Watrin F, Mebarek S, Marly F, Roussel M, Gire C, Diene G, Tauber M, Muscatelli F, Hilaire G (2008) Necdin plays a role in the serotonergic modulation of the mouse respiratory network: implication for Prader-Willi syndrome. J Neurosci 28:1745–1755.
- Zhao ZQ, Chiechio S, Sun YG, Zhang KH, Zhao CS, Scott M, Johnson RL, Deneris ES, Renner KJ, Gereau RW 4th, Chen ZF (2007) Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 27:6045– 6053.